BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016; 22(34): 7824-7840 [PMID: 27678366 DOI: 10.3748/wjg.v22.i34.7824] [Cited by in CrossRef: 394] [Cited by in F6Publishing: 334] [Article Influence: 65.7] [Reference Citation Analysis]
Number Citing Articles
1 Ejtehadi F, Farahvashi P, Shamsaeefar A, Niknam R, Sivandzadeh GR, Aminlari L, Motazedian N, Kazemi K, Nikoupour H, Nikeghbalian S, Eghlimi H, Taghavi A, Fattahi M, Bagheri Lankarani K, Malek-hosseini SA. Clinical Course and Outcome of Liver Transplantation in Patients with Hepatitis C in Iran. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.108405] [Reference Citation Analysis]
2 Qu LX, Shi Y, Chen KY, Lu YH, Ren H. The distribution of hepatitis C virus infection in Shanghai, China: a time-spatial study. BMC Infect Dis 2021;21:974. [PMID: 34536999 DOI: 10.1186/s12879-021-06577-8] [Reference Citation Analysis]
3 Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A, Cortinovis DL. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. Crit Rev Oncol Hematol 2018;129:27-39. [PMID: 30097235 DOI: 10.1016/j.critrevonc.2018.06.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
4 Voils CI, King HA, Thorpe CT, Blalock DV, Kronish IM, Reeve BB, Boatright C, Gellad ZF. Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment. Dig Dis Sci 2019;64:2784-97. [PMID: 31037593 DOI: 10.1007/s10620-019-05621-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia–Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57-73. [DOI: 10.1038/s41575-018-0055-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 21.5] [Reference Citation Analysis]
6 Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. J Viral Hepat 2018;25:945-51. [DOI: 10.1111/jvh.12886] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
7 Akimov IA, Timofeev DI, Mavzyutov AR, Ivanov MK. Detection of circulating HCV recombinant form RF1_2k/1b in blood serum of patients by real-time RT-PCR. Klin Lab Diagn 2021;66:122-8. [PMID: 33734647 DOI: 10.51620/0869-2084-2021-66-2-122-128] [Reference Citation Analysis]
8 Nguyen T, Pham T, Tang HK, Phan L, Mize G, Lee WM, Gish R, Trang A, Le A, Phan HT, Nguyen BT, Dao DY. Unmet needs in occupational health: prevention and management of viral hepatitis in healthcare workers in Ho Chi Minh City, Vietnam: a mixed-methods study. BMJ Open 2021;11:e052668. [PMID: 34642198 DOI: 10.1136/bmjopen-2021-052668] [Reference Citation Analysis]
9 Tisthammer KH, Dong W, Joy JB, Pennings PS. Comparative Analysis of Within-Host Mutation Patterns and Diversity of Hepatitis C Virus Subtypes 1a, 1b, and 3a. Viruses 2021;13:511. [PMID: 33808782 DOI: 10.3390/v13030511] [Reference Citation Analysis]
10 Choi HY, Kim Y, Cho H, Kim BH, Ki M. Risk of diabetes in viral hepatitis B or C patients compared to that in noninfected individuals in Korea, 2002-2013: A population-based cohort study. J Viral Hepat 2018;25:272-80. [DOI: 10.1111/jvh.12815] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ouoba S, Ouedraogo JCRP, Lingani M, E B, Hussain MRA, Ko K, Nagashima S, Sugiyama A, Akita T, Tinto H, Tanaka J. Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis. BMC Infect Dis 2021;21:1126. [PMID: 34724902 DOI: 10.1186/s12879-021-06817-x] [Reference Citation Analysis]
12 Kong F, Wen X, Wen X, Wang X, Wu G, Lin S, Wang L, Xing H, Yan X, Zheng S, Ning Q, Wang Z, Zhang L, Lin J, Tong Z, Huang C, Su M, Tong L, Jia J, Xin Y, Zhu Q, Wang J, Chen L, Li X, Wu X, Niu D, Liu Q, Wei W, Zhang Y, Li G, Niu J. Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial. J Gastroenterol Hepatol 2021. [PMID: 33491236 DOI: 10.1111/jgh.15412] [Reference Citation Analysis]
13 Wei S, Lei Y, Yang J, Wang X, Shu F, Wei X, Lin F, Li B, Cui Y, Zhang H, Wei S. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes. Vaccine 2018;36:2273-81. [PMID: 29576303 DOI: 10.1016/j.vaccine.2018.03.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
14 Shafie AA, Abu Hassan MR, Abdul Ghani N, Chew BH, Mohammed NS. Cost analysis of chronic hepatitis C virus management in a Malaysia tertiary hospital. J Pharm Health Serv Res 2018;9:141-4. [DOI: 10.1111/jphs.12210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Kao JH, Lin CY, Chuang WL, Cheng YY, Hu JY, Liang WK, Friebe P, Palmer S, Huang CS. Clinical evaluation of IntelliPlexTM HCV genotyping kit for hepatitis C virus genotyping. Diagn Microbiol Infect Dis 2019;94:344-8. [PMID: 30975461 DOI: 10.1016/j.diagmicrobio.2019.02.020] [Reference Citation Analysis]
16 Krapchev VB, Rychłowska M, Chmielewska A, Zimmer K, Patel AH, Bieńkowska-Szewczyk K. Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice. Virology 2018;519:33-41. [PMID: 29631174 DOI: 10.1016/j.virol.2018.03.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Chatterjee K, Gupta R, Omar BJ, Gupta P, Kalita D. Genotypic distribution of hepatitis C virus in Uttarakhand. Indian J Med Microbiol 2021:S0255-0857(21)04133-5. [PMID: 34210508 DOI: 10.1016/j.ijmmb.2021.06.009] [Reference Citation Analysis]
18 [DOI: 10.1063/1.5127485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Wu BR, Eltahla AA, Keoshkerian E, Walker MR, Underwood A, Brasher NA, Agapiou D, Lloyd AR, Bull RA. A method for detecting hepatitis C envelope specific memory B cells from multiple genotypes using cocktail E2 tetramers. J Immunol Methods 2019;472:65-74. [PMID: 31226262 DOI: 10.1016/j.jim.2019.06.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
20 Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018;8:12266. [PMID: 30116054 DOI: 10.1038/s41598-018-30528-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
21 Asghar MS, Rasheed U, Hassan M, Akram M, Yaseen R, Fayaz B. A CROSS-SECTIONAL SCREENING SURVEY ON THE SEROPREVALENCE OF HEPATITIS B AND HEPATITIS C AMONGST THE GENERAL POPULATION OF RURAL DISTRICTS OF SINDH, PAKISTAN. Arq Gastroenterol 2021;58:150-6. [PMID: 34231661 DOI: 10.1590/S0004-2803.202100000-26] [Reference Citation Analysis]
22 Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N; EASL HEPAHEALTH Steering Committee. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718-735. [PMID: 29777749 DOI: 10.1016/j.jhep.2018.05.011] [Cited by in Crossref: 211] [Cited by in F6Publishing: 190] [Article Influence: 52.8] [Reference Citation Analysis]
23 Wong YJ, Thurairajah PH, Kumar R, Tan J, Fock KM, Law NM, Li W, Kwek A, Tan YB, Koh J, Lee ZC, Kumar LS, Teo EK, Ang TL. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. J Gastroenterol Hepatol. 2020;. [PMID: 33217040 DOI: 10.1111/jgh.15324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
24 Aziz H, Fatima S, Faheem M. Indeterminate Prediction of Hepatitis C Virus Genotype by Commercial Real-Time Polymerase Chain Reaction Assay Resolving by Sequencing to Avoid the Consequence of Inaccurate Typing. Viral Immunol 2020;33:507-13. [PMID: 32429831 DOI: 10.1089/vim.2019.0162] [Reference Citation Analysis]
25 Candotti D, Sauvage V, Cappy P, Boullahi MA, Bizimana P, Mbensa GO, Oumar Coulibaly S, Rakoto Alson AO, Soumana H, Tagny-Tayou C, Murphy EL, Laperche S; Francophone Africa Transfusion Research Network. High rate of hepatitis C virus and human immunodeficiency virus false-positive results in serologic screening in sub-Saharan Africa: adverse impact on the blood supply. Transfusion 2020;60:106-16. [PMID: 31777096 DOI: 10.1111/trf.15593] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
26 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
27 Tsai SM, Kao JT, Tsai YF. Illness trajectory of initial infection for patients with hepatitis C: A qualitative study. Nurs Health Sci 2019;21:112-8. [PMID: 30251452 DOI: 10.1111/nhs.12568] [Reference Citation Analysis]
28 Ahmed M. Era of direct acting anti-viral agents for the treatment of hepatitis C. World J Hepatol 2018; 10(10): 670-684 [PMID: 30386460 DOI: 10.4254/wjh.v10.i10.670] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
29 Lake EA, Fite RO, Gebrekirstos LG, Gebremedhin MH, Obsa MS, Gelaw KA. Seroprevalence of hepatitis c virus infection among blood donors in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis 2021;21:131. [PMID: 33516181 DOI: 10.1186/s12879-021-05827-z] [Reference Citation Analysis]
30 Gayam V, Khalid M, Mandal AK, Hussain MR, Mukhtar O, Gill A, Garlapati P, Shrestha B, Guss D, Sherigar J, Mansour M, Mohanty S. Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting. Gastroenterology Res 2018;11:130-7. [PMID: 29707080 DOI: 10.14740/gr999w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
31 Ejeh S, Uzairu A, Shallangwa GA, Abechi SE. Computer-aided identification of a series of novel ligands showing high potency as hepatitis C virus NS3/4A protease inhibitors. Bull Natl Res Cent 2021;45. [DOI: 10.1186/s42269-020-00467-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Yu ML, Tsai WL, Chu CJ, Kao JH. Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study. Kaohsiung J Med Sci 2021;37:245-52. [PMID: 33089964 DOI: 10.1002/kjm2.12317] [Reference Citation Analysis]
33 Kiprijanovska S, Stefanovska ES, Noveski P, Ivanova VC, Plaseska-karanfilska D. Influence of OASL gene polymorphisms on host response to interferon therapy in chronic hepatitis C virus patients. The EuroBiotech Journal 2017;1:117-25. [DOI: 10.24190/issn2564-615x/2017/02.02] [Reference Citation Analysis]
34 Fernandes RS, Freire MCLC, Bueno RV, Godoy AS, Gil LHVG, Oliva G. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses. Viruses 2020;12:E598. [PMID: 32486283 DOI: 10.3390/v12060598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
35 Hamza A, Ahmad I, Uneeb M. Fuzzy logic and Lyapunov-based non-linear controllers for HCV infection. IET Syst Biol 2021;15:53-71. [PMID: 33780147 DOI: 10.1049/syb2.12014] [Reference Citation Analysis]
36 Meshram RJ, Kathwate GH, Gacche RN. Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections. Arch Virol 2022. [PMID: 35089390 DOI: 10.1007/s00705-022-05375-0] [Reference Citation Analysis]
37 Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, Razzack AA, Solimando AG, Thompson A, Andrews K, Enebong Nya G, Ahmad S, Ranaldo R, Cozzolongo R, Shahini E. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg 2021;84:637-56. [PMID: 34965046 DOI: 10.51821/84.4.015] [Reference Citation Analysis]
38 Tzarum N, Wilson IA, Law M. The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein. Front Immunol 2018;9:1315. [PMID: 29951061 DOI: 10.3389/fimmu.2018.01315] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
39 Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S. Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health 2020;13:773-83. [PMID: 31870632 DOI: 10.1016/j.jiph.2019.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
40 Andrade XA, Paz LH, Nassar M, Oramas DM, Fuentes HE, Kovarik P, Mishra S, Singh A. Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. Acta Haematol 2018;139:77-80. [PMID: 29393087 DOI: 10.1159/000484653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
41 El-Shabrawi M, Baroudy S, Hassanin F, Behairy AS, Yakoot M, Ahmed A. Follow-up of chronic paediatric hepatitis C virus in a low-/middle-income country. Acta Paediatr 2020;109:2699-705. [PMID: 32358871 DOI: 10.1111/apa.15333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Lambdin BH, Lorvick J, Mbwambo JK, Rwegasha J, Hassan S, Lum P, Kral AH. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania. Int J Drug Policy 2017;45:64-9. [PMID: 28628854 DOI: 10.1016/j.drugpo.2017.05.043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
43 Figueiredo AS, Lampe E, de Albuquerque PPLF, Chalhoub FLL, de Filippis AMB, Villar LM, Cruz OG, Pinto MA, de Oliveira JM. Epidemiological investigation and analysis of the NS5B gene and protein variability of non-primate hepacivirus in several horse cohorts in Rio de Janeiro state, Brazil. Infect Genet Evol 2018;59:38-47. [PMID: 29413884 DOI: 10.1016/j.meegid.2018.01.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
44 Wu D, Hu S, Chen G, Chen L, Liu J, Chen W, Lv Y, Chen X, Lin S, Wu F. Association of hepatitis C infection and risk of kidney cancer: A systematic review and meta-analysis of observational studies. J Viral Hepat 2021;28:226-35. [PMID: 33141502 DOI: 10.1111/jvh.13434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Gewaid H, Aoyagi H, Arita M, Watashi K, Suzuki R, Sakai S, Kumagai K, Yamaji T, Fukasawa M, Kato F, Hishiki T, Mimata A, Sakamaki Y, Ichinose S, Hanada K, Muramatsu M, Wakita T, Aizaki H. Sphingomyelin Is Essential for the Structure and Function of the Double-Membrane Vesicles in Hepatitis C Virus RNA Replication Factories. J Virol. 2020;94. [PMID: 32938759 DOI: 10.1128/jvi.01080-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
46 Miranda NTGP, de Souza RL, Monteiro JC, Costa IB, Siravenha LQ, da Luz ALB, de Almeida NCC, Oliveira-Filho AB, Laurentino RV, Machado LFA. Seroprevalence of HBV and HCV in female sex workers from four cities in the state of Pará, northern Brazil. J Med Virol 2021;93:3730-7. [PMID: 33368401 DOI: 10.1002/jmv.26759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Gicquelais RE, Foxman B, Coyle J, Eisenberg MC. Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. Epidemics 2019;27:86-95. [PMID: 30930214 DOI: 10.1016/j.epidem.2019.02.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
48 Van Haele M, Snoeck J, Roskams T. Human Liver Regeneration: An Etiology Dependent Process. Int J Mol Sci 2019;20:E2332. [PMID: 31083462 DOI: 10.3390/ijms20092332] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
49 Yasseen AS 3rd, Kwong JC, Feld JJ, Janjua NZ, Greenaway C, Lapointe-Shaw L, Sherman M, Mazzulli T, Kustra R, MacDonald L, Sander B, Crowcroft NS. Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents. Liver Int 2021;41:1775-88. [PMID: 33655665 DOI: 10.1111/liv.14840] [Reference Citation Analysis]
50 Fofiu C, Boeriu A, Coman F, Fofiu A, Panic N, Bulajic M, Dobru D. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients. Ann Hepatol 2019;18:137-43. [PMID: 31113582 DOI: 10.5604/01.3001.0012.7905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Kim KA, Lee JS. Prevalence, Awareness, and Treatment of Hepatitis C Virus Infection in South Korea: Evidence from the Korea National Health and Nutrition Examination Survey. Gut Liver 2020;14:644-51. [PMID: 31842525 DOI: 10.5009/gnl19272] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Wei B, Ji F, Yeo YH, Ogawa E, Stave CD, Dang S, Li Z, Furusyo N, Cheung RC, Nguyen MH. Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia. BMJ Open Gastroenterol 2018;5:e000209. [PMID: 30147941 DOI: 10.1136/bmjgast-2018-000209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
53 Irekeola AA, Malek NA, Wada Y, Mustaffa N, Muhamad NI, Shueb RH. Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. PLoS One 2021;16:e0251673. [PMID: 34014997 DOI: 10.1371/journal.pone.0251673] [Reference Citation Analysis]
54 Heiza M, Elmola K, Salama B. Unsafe Practices Associated with HCV Infection Among Adults: A Case Control Study. Int J Prev Med 2021;12:60. [PMID: 34447502 DOI: 10.4103/ijpvm.IJPVM_94_20] [Reference Citation Analysis]
55 Belperio PS, Shahoumian TA, Loomis TP, Mole LA, Backus LI. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol 2019;70:15-23. [PMID: 30266283 DOI: 10.1016/j.jhep.2018.09.018] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
56 Noreen A, Alam N, Syed Z, Aftab A, Shamim F, Najeebullah S, Khan D, Kakar SJ, Ahmed T, Adnan F. Prevalence and assessment of the associated risk factors of hepatitis B and C infections in the low socioeconomic communities. Future Virology. [DOI: 10.2217/fvl-2021-0060] [Reference Citation Analysis]
57 Tagnouokam-Ngoupo PA, Ngoufack MN, Kenmoe S, Lissock SF, Amougou-Atsama M, Banai R, Ngono L, Njouom R. Hepatitis C virus genotyping based on Core and NS5B regions in Cameroonian patients. Virol J 2019;16:101. [PMID: 31399103 DOI: 10.1186/s12985-019-1214-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kaba A, Yamanaga S, Hidaka Y, Toyoda M, Kashima M, Takekuma Y, Inadome A, Yokomizo H, Miyata A. Glecaprevir/Pibrentasvir and Renal Dysfunction in Deceased Donor Renal Transplantation: A Case Report. Transplant Proc 2022:S0041-1345(21)00950-7. [PMID: 35120765 DOI: 10.1016/j.transproceed.2021.12.028] [Reference Citation Analysis]
59 Uribe-Noguez LA, Ocaña-Mondragón A, Mata-Marín JA, Cázares-Cortázar A, Ribas-Aparicio RM, Gómez-Torres ME, Gaytán-Martínez J, Martínez-Rodríguez ML. Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir. J Infect Chemother 2018;24:928-31. [PMID: 29773440 DOI: 10.1016/j.jiac.2018.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
60 Wei B, Ji F, Yeo YH, Ogawa E, Zou B, Stave CD, Dang S, Li Z, Furusyo N, Cheung RC, Nguyen MH. Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2018;5:e000207. [PMID: 30002863 DOI: 10.1136/bmjgast-2018-000207] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
61 Rostoker G, Vaziri ND. Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution. Hemodial Int 2017;21 Suppl 1:S68-77. [PMID: 28332306 DOI: 10.1111/hdi.12557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
62 Khuroo MS, Sofi AA. The Discovery of Hepatitis Viruses: Agents and Disease. J Clin Exp Hepatol. 2020;10:391-401. [PMID: 32655240 DOI: 10.1016/j.jceh.2020.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Behzadifar M, Gorji HA, Bragazzi NL. The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. Arch Virol 2018;163:1131-40. [DOI: 10.1007/s00705-018-3767-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
64 Hardikar W. Viral hepatitis. J Paediatr Child Health 2019;55:1038-43. [DOI: 10.1111/jpc.14562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
65 Morikawa K, Nakamura A, Shimazaki T, Sakamoto N. Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence. Drug Des Devel Ther 2018;12:2749-56. [PMID: 30233138 DOI: 10.2147/DDDT.S133697] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
66 Bendich I, Takemoto S, Patterson JT, Monto A, Barber TC, Kuo AC. Preoperative Treatment of Hepatitis C Is Associated With Lower Prosthetic Joint Infection Rates in US Veterans. J Arthroplasty 2019;34:S319-S326.e1. [PMID: 30930157 DOI: 10.1016/j.arth.2019.02.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
67 Rammohan A. Current management & future directions in post-liver transplant recurrence of viral hepatitis. Journal of Liver Transplantation 2021;3:100027. [DOI: 10.1016/j.liver.2021.100027] [Reference Citation Analysis]
68 Somerville L, Doucette K. Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation. Curr Infect Dis Rep 2018;20:18. [PMID: 29789956 DOI: 10.1007/s11908-018-0625-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
69 Aibekova L, Bexeitova A, Aldabergenova A, Hortelano G, Ge Z, Yi F, Shao Y, DeHovitz J, Vermund SH, Ali S. Transmission of HIV and HCV within Former Soviet Union Countries. Can J Gastroenterol Hepatol 2020;2020:9701920. [PMID: 32733822 DOI: 10.1155/2020/9701920] [Reference Citation Analysis]
70 Nasir IA, Yakubu S, Mustapha JO. Epidemiology and Synergistic Hepatopathology of Malaria and Hepatitis C Virus Coinfection. Virology (Auckl) 2017;8:1178122X17724411. [PMID: 28814840 DOI: 10.1177/1178122X17724411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
71 Zhuang J, Yin J, Lv S, Wang B, Mu Y. Advanced "lab-on-a-chip" to detect viruses - Current challenges and future perspectives. Biosens Bioelectron 2020;163:112291. [PMID: 32421630 DOI: 10.1016/j.bios.2020.112291] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 16.5] [Reference Citation Analysis]
72 Echeverría N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J. In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? . World J Hepatol 2021; 13(10): 1234-1268 [PMID: 34786164 DOI: 10.4254/wjh.v13.i10.1234] [Reference Citation Analysis]
73 Henriquez-Camacho C, Serre N, Norman F, Sánchez-Montalvá A, Torrús D, Goikoetxea AJ, Herrero-Martínez JM, Ruiz-Giardín JM, Treviño B, Monge-Maillo B, Molina I, Rodríguez A, García M, López-Vélez R, Pérez-Molina JA; Redivi Study Group. Clinicoepidemiological characteristics of viral hepatitis in migrants and travellers of the +Redivi network. Travel Med Infect Dis 2019;29:51-7. [PMID: 30738196 DOI: 10.1016/j.tmaid.2019.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Aljowaie RM, Almajhdi FN, Ali HH, El-Wetidy MS, Shier MK. Inhibition of hepatitis C virus genotype 4 replication using siRNA targeted to the viral core region and the CD81 cellular receptor. Cell Stress Chaperones 2020;25:345-55. [PMID: 32060691 DOI: 10.1007/s12192-020-01077-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
75 Kichatova VS, Kyuregyan KK, Soboleva NV, Karlsen AA, Isaeva OV, Isaguliants MG, Mikhailov MI. Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. J Immunol Res 2018;2018:7685371. [PMID: 29577052 DOI: 10.1155/2018/7685371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
76 Petruzziello A, Sabatino R, Loquercio G, Guzzo A, Di Capua L, Labonia F, Cozzolino A, Azzaro R, Botti G. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS One 2019;14:e0212033. [PMID: 30785909 DOI: 10.1371/journal.pone.0212033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
77 Hostager R, Ragonnet-Cronin M, Murrell B, Hedskog C, Osinusi A, Susser S, Sarrazin C, Svarovskaia E, Wertheim JO. Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage. Virus Evol 2019;5:vez041. [PMID: 31616569 DOI: 10.1093/ve/vez041] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Egerman RS. New Antiviral Agents for Treatment of Hepatitis C. Clin Obstet Gynecol 2019;62:823-34. [PMID: 31094712 DOI: 10.1097/GRF.0000000000000457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Riaz S, Tiwana H, Adil M, Ali K, Javed T. Anti-hepatitis C virus and synergistic potential of Syzgium cumine a bioassay guided screening in liver-infected hepatocytes. Arch Microbiol 2022;204. [DOI: 10.1007/s00203-021-02646-3] [Reference Citation Analysis]
80 Zha J, Ding B, Wang H, Zhao W, Yu C, Alves K, Mobashery N, Luo Y, Menon RM. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients. Eur J Drug Metab Pharmacokinet 2019;44:43-52. [PMID: 29909549 DOI: 10.1007/s13318-018-0492-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Hsieh M, Kao T, Hsieh T, Kao C, Peng C, Lai H, Chuang P, Kao J. Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study. Therapeutic Advances in Chronic Disease 2022;13:204062232110676. [DOI: 10.1177/20406223211067631] [Reference Citation Analysis]
82 Batsaikhan B, Huang C, Yeh M, Huang C, Liang P, Hsieh M, Huang J, Yu M, Chuang W, Lee J, Lee P, Dai C. Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients: Cryoglobulinemia and liver fibrosis in CHC. Journal of Gastroenterology and Hepatology 2018;33:1897-903. [DOI: 10.1111/jgh.14275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
83 Sohail MU, Al Thani AA, Yassine HM. Comparative Phylogenetic and Residue Analysis of Hepatitis C Virus E1 Protein from the Middle East and North Africa Region. Hepat Mon 2019;19. [DOI: 10.5812/hepatmon.92437] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Roumy V, Ruiz L, Ruiz Macedo JC, Gutierrez-Choquevilca AL, Samaillie J, Encinas LA, Mesia WR, Ricopa Cotrina HE, Rivière C, Sahpaz S, Bordage S, Garçon G, Dubuisson J, Anthérieu S, Seron K, Hennebelle T. Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource. J Ethnopharmacol 2020;255:112735. [PMID: 32147478 DOI: 10.1016/j.jep.2020.112735] [Reference Citation Analysis]
85 Santos TPS, Pereira MM, Schinoni MI, Sampaio GP, Aras R Jr, Atta MLS, Atta AM. Atherogenic cytokines and chemokines in chronic hepatitis C are not associated with the presence of cardiovascular diseases. Cytokine 2019;115:24-31. [PMID: 30771700 DOI: 10.1016/j.cyto.2018.12.005] [Reference Citation Analysis]
86 Tzarum N, Giang E, Kadam RU, Chen F, Nagy K, Augestad EH, Velázquez-Moctezuma R, Keck ZY, Hua Y, Stanfield RL, Dreux M, Prentoe J, Foung SKH, Bukh J, Wilson IA, Law M. An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. Sci Adv 2020;6:eabb5642. [PMID: 32754640 DOI: 10.1126/sciadv.abb5642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
87 Macek Jílková Z, Seigneurin A, Coppard C, Ouaguia L, Aspord C, Marche PN, Leroy V, Decaens T. Circulating IL-13 Is Associated with De Novo Development of HCC in HCV-Infected Patients Responding to Direct-Acting Antivirals. Cancers (Basel) 2020;12:E3820. [PMID: 33352852 DOI: 10.3390/cancers12123820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
88 Sedeño-Monge V, Laguna-Meraz S, Santos-López G, Panduro A, Sosa-Jurado F, Jose-Abrego A, Meléndez-Mena D, Muñoz-Ramírez MA, Cosme-Chávez M, Roman S. A comprehensive update of the status of hepatitis C virus (HCV) infection in Mexico-A systematic review and meta-analysis (2008-2019). Ann Hepatol 2021;20:100292. [PMID: 33259949 DOI: 10.1016/j.aohep.2020.100292] [Reference Citation Analysis]
89 Ahn SH, Choe WH, Kim YJ, Heo J, Latarska-Smuga D, Kang J, Paik SW. Impact of Interferon-Based Treatment on Quality of Life and Work-Related Productivity of Korean Patients with Chronic Hepatitis C. Gut Liver 2020;14:368-76. [PMID: 31533395 DOI: 10.5009/gnl18100] [Reference Citation Analysis]
90 Davis SM, Davidov D, Kristjansson AL, Zullig K, Baus A, Fisher M. Qualitative case study of needle exchange programs in the Central Appalachian region of the United States. PLoS One 2018;13:e0205466. [PMID: 30312333 DOI: 10.1371/journal.pone.0205466] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
91 Al-Busafi SA, Al-Shuaili H, Omar H, Al-Zuhaibi H, Jeyaseelan L, Al-Naamani K. Epidemiology of Chronic Hepatitis C Infections at a Tertiary Care Centre in Oman. Sultan Qaboos Univ Med J 2017;17:e404-10. [PMID: 29372081 DOI: 10.18295/squmj.2017.17.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Zayed RA, Omran D, Zayed AA, Elmessery LO. Determinants of Infection Outcome in HCV-Genotype 4. Viral Immunol. 2017;30:560-567. [PMID: 28731371 DOI: 10.1089/vim.2017.0071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
93 Badawi A, Di Giuseppe G, Arora P. Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017). PLoS One 2018;13:e0208839. [PMID: 30540839 DOI: 10.1371/journal.pone.0208839] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
94 Andrade E, Rocha D, Fontana-Maurell M, Costa E, Ribeiro M, de Godoy DT, Ferreira AGP, Tanuri A, Alvarez P, Brindeiro R. One-step real-time PCR assay for detection and quantification of RNA HCV to monitor patients under treatment in Brazil. Braz J Infect Dis 2018;22:418-23. [PMID: 30243981 DOI: 10.1016/j.bjid.2018.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Batsaikhan B, Huang CI, Yeh ML, Huang CF, Hou NJ, Lin ZY, Chen SC, Huang JF, Yu ML, Chuang WL, Lee JC, Dai CY. The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. Oncotarget 2018;9:21313-21. [PMID: 29765541 DOI: 10.18632/oncotarget.25092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
96 Le Ngoc C, Tran Thi Thanh T, Tran Thi Lan P, Nguyen Mai T, Nguyen Hoa T, Nghiem My N, Le Van T, Le Manh H, Le Thanh P, Nguyen Van Vinh C, Thwaites G, Cooke G, Heilek GM, Shikuma C, Le T, Baker S, Rahman M; VIZIONS consortium. Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. PLoS One 2019;14:e0212734. [PMID: 30865664 DOI: 10.1371/journal.pone.0212734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
97 Arba M, Wahyudi ST, Zubair MS, Brunt D, Singh M, Wu C. Binding of GS-461203 and Its Halogen Derivatives to HCV Genotype 2a RNA Polymerase Drug Resistance Mutants. Sci Pharm 2022;90:26. [DOI: 10.3390/scipharm90020026] [Reference Citation Analysis]
98 Li XM, Qiu RX, Song CH, Huang QH, Wang XD, Hu ZT, He XZ, Ye XY, Huang XG, Zheng FF, Lin GX. Genotype and genetic variation of HCV infections with low-risk factors in Putian coastal regions, China. Epidemiol Infect 2017;145:3385-97. [PMID: 29081304 DOI: 10.1017/S0950268817002357] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
99 Kleefeld F, Arendt G, Neuen-Jacob E, Maschke M, Husstedt I, Obermann M, Schmidt H, Hahn K; Deutsche Gesellschaft für Neuro-AIDS und Neuro-Infektiologie (DGNANI). [Neurological complications of hepatitis C infections]. Nervenarzt 2021;92:144-9. [PMID: 33001263 DOI: 10.1007/s00115-020-00999-6] [Reference Citation Analysis]
100 Njiomegnie GF, Read SA, Fewings N, George J, McKay F, Ahlenstiel G. Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. J Clin Med. 2020;9. [PMID: 32268490 DOI: 10.3390/jcm9041030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
101 Zając M, Muszalska I, Sobczak A, Dadej A, Tomczak S, Jelińska A. Hepatitis C - New drugs and treatment prospects. Eur J Med Chem 2019;165:225-49. [PMID: 30685524 DOI: 10.1016/j.ejmech.2019.01.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
102 Jiménez-mendoza J, Rivera-lópez F, González-lara M, Valdez-echeverría R, Castro-narro G, Tore A, Uscanga-domínguez L, Moctezuma-velázquez C. Seroprevalence of hepatitis B and C viruses in moderate and severe COVID-19 inpatients: a cross-sectional study at a referral center in Mexico. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100684] [Reference Citation Analysis]
103 Adeboyejo K, Grosche VR, José DP, Ferreira GM, Shimizu JF, King BJ, Tarr AW, Soares MMCN, Ball JK, Mcclure CP, Jardim ACG. Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from São Paulo state, Brazil. Access Microbiology 2022;4. [DOI: 10.1099/acmi.0.000326] [Reference Citation Analysis]
104 Chin J, Reyes AC, Chen C, Over A, Hsu E, Rich S, Lomiguen C. Undergraduate Medical School Health Fair Hepatitis Screenings: Utilizing Non-Profit Community Organizations. Int J Prev Med 2021;12:93. [PMID: 34584658 DOI: 10.4103/ijpvm.IJPVM_68_20] [Reference Citation Analysis]
105 Bowsher M, Hiebert S, Li R, Wang AX, Friborg J, Yu F, Hernandez D, Wang Y, Klei H, Rajamani R, Mosure K, Knipe JO, Meanwell NA, Mcphee F, Scola PM. The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease. Bioorganic & Medicinal Chemistry Letters 2018;28:43-8. [DOI: 10.1016/j.bmcl.2017.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
106 Pawlowska M, Sobolewska-Pilarczyk M, Domagalski K. Hepatitis C virus infection in children in the era of direct-acting antiviral. World J Gastroenterol 2018; 24(24): 2555-2566 [PMID: 29962813 DOI: 10.3748/wjg.v24.i24.2555] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
107 Bhebhe L, Anderson M, Souda S, Choga WT, Zumbika E, Shaver ZM, Mbangiwa T, Phinius BB, Banda CC, Melamu P, Musonda RM, Essex M, Blackard JT, Moyo S, Gaseitsiwe S. Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study. BMC Infect Dis 2019;19:875. [PMID: 31640596 DOI: 10.1186/s12879-019-4514-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
108 Li H, Hu L, Wang L, Wang Y, Shao M, Chen Y, Wu W, Wang L. Iron Activates cGAS-STING Signaling and Promotes Hepatic Inflammation. J Agric Food Chem 2022. [PMID: 35133148 DOI: 10.1021/acs.jafc.1c06681] [Reference Citation Analysis]
109 Elsadek HM, Abdelbaser ES, Emara MH, Soliman HH, Farag AA. Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. Eur J Gastroenterol Hepatol 2020;32:1046-53. [PMID: 33216478 DOI: 10.1097/MEG.0000000000001695] [Reference Citation Analysis]
110 Matsumoto K, Miyaaki H, Fukushima M, Sasaki R, Haraguchi M, Miuma S, Nakao K. The impact of single-nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct-acting antiviral drugs for hepatitis C infection. Biomed Rep 2022;16:9. [PMID: 34987793 DOI: 10.3892/br.2021.1492] [Reference Citation Analysis]
111 Travaglino A, Varricchio S, Pace M, Iuliano A, Picardi M, Tranfa F, Staibano S, Mascolo M. Hepatitis C virus in MALT-lymphoma of the ocular adnexa. Pathol Res Pract 2020;216:152864. [PMID: 32088088 DOI: 10.1016/j.prp.2020.152864] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
112 Abaalkhail F, Al-hamoudi W, Altraif I, Mohamed H, Aleid H, Broering D, Alqahtani S. Treatment with Grazoprevir/Elbasvir in Post-kidney Transplant Patients with Hepatitis C Virus Genotype 4 Infection. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.110260] [Reference Citation Analysis]
113 Wang H, Xin X, Wang M, Han L, Li J, Hao Y, Zheng C, Shen C. Myxovirus resistance protein A inhibits hepatitis C virus replication through JAK-STAT pathway activation. Arch Virol 2018;163:1429-38. [PMID: 29417241 DOI: 10.1007/s00705-018-3748-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
114 Pheng P, Meyer L, Ségéral O, Chea P, Yi S, Tuot S, Kaldor JM, Saphonn V. Hepatitis C seroprevalence among people living with HIV/AIDS and pregnant women in four provinces in Cambodia: an integrated bio-behavioral survey. BMC Infect Dis 2022;22:177. [PMID: 35193496 DOI: 10.1186/s12879-022-07163-2] [Reference Citation Analysis]
115 Bawazir A, AlGusheri F, Jradi H, AlBalwi M, Abdel-Gader AG. Hepatitis C virus genotypes in Saudi Arabia: a future prediction and laboratory profile. Virol J 2017;14:208. [PMID: 29096662 DOI: 10.1186/s12985-017-0873-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
116 Zhang H, Ren R, Liu J, Mao Y, Pan G, Men K, Ma L. Health-Related Quality of Life among Patients with Hepatitis C Virus Infection: A Cross-Sectional Study in Jianping County of Liaoning Province, China. Gastroenterol Res Pract 2020;2020:6716103. [PMID: 32411200 DOI: 10.1155/2020/6716103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
117 Mohamadi M, Azarbayjani K, Mozhgani SH, Bamdad T, Alamdary A, Nikoo HR, Hashempour T, Hedayat Yaghoobi M, Ajorloo M. Hepatitis C virus alternative reading frame protein (ARFP): Production, features, and pathogenesis. J Med Virol 2020. [PMID: 32470157 DOI: 10.1002/jmv.26091] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 Hamburg-Shields E, Prasad M. Infectious Hepatitis in Pregnancy. Clin Obstet Gynecol 2020;63:175-92. [PMID: 31895116 DOI: 10.1097/GRF.0000000000000512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Duan X, Liu X, Li W, Holmes JA, Kruger AJ, Yang C, Li Y, Xu M, Ye H, Li S, Liao X, Sheng Q, Chen D, Shao T, Cheng Z, Kaj B, Schaefer EA, Li S, Chen L, Lin W, Chung RT. Microrna-130a Downregulates HCV Replication through an atg5-Dependent Autophagy Pathway. Cells 2019;8:E338. [PMID: 30974864 DOI: 10.3390/cells8040338] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
120 Okafor IM, Ugwu SO, Okoroiwu HU. Hepatitis C virus infection and its associated factors among prisoners in a Nigerian prison. BMC Gastroenterol 2020;20:360. [PMID: 33126856 DOI: 10.1186/s12876-020-01504-8] [Reference Citation Analysis]
121 Huang R, Rao H, Xie Q, Gao Z, Li W, Jiang D, Mo H, Massetto B, Stamm LM, Brainard DM, Wei L. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. J Med Virol 2019;91:1313-8. [PMID: 30861150 DOI: 10.1002/jmv.25454] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
122 Gaballah AM, Esawy MM. Comparison of 2 different antibody assay methods, Elecsys Anti-HCVII (Roche) and Vidas Anti-HCV (Biomerieux), for the detection of antibody to hepatitis C virus in Egypt. Diagn Microbiol Infect Dis 2018;92:107-11. [PMID: 29925467 DOI: 10.1016/j.diagmicrobio.2018.05.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
123 Shengir M, Elgara M, Sebastiani G. Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. World J Gastroenterol 2021; 27(17): 1959-1972 [PMID: 34007133 DOI: 10.3748/wjg.v27.i17.1959] [Reference Citation Analysis]
124 Mizuochi T, Takano T, Yanagi T, Ushijima K, Suzuki M, Miyoshi Y, Ito Y, Inui A, Tajiri H. Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan. J Gastroenterol. 2018;53:419-426. [PMID: 28567493 DOI: 10.1007/s00535-017-1351-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
125 Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53. [PMID: 27752280 DOI: 10.1186/s13027-016-0099-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
126 Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
127 Villar LM, de Paula VS, do Lago BV, Miguel JC, Cruz HM, Portilho MM, Marques VA, Ravier RP, Lo Castro I, Cuello H, Espul C. Epidemiology of hepatitis B and C virus infection in Central West Argentina. Arch Virol 2020;165:913-22. [PMID: 32078045 DOI: 10.1007/s00705-020-04540-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
128 Daw MA, Buktir Ali LA, Daw AM, Sifennasr NEM, Dau AA, Agnan MM, El-Bouzedi A; In association with the Libyan Study Group of Hepatitis & HIV. The geographic variation and spatiotemporal distribution of hepatitis C virus infection in Libya: 2007-2016. BMC Infect Dis 2018;18:594. [PMID: 30466399 DOI: 10.1186/s12879-018-3471-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
129 Buganza-torio E, Doucette KE. Management of Viral Hepatitis in Solid Organ Transplant Recipients. Infectious Disease Clinics of North America 2018;32:635-50. [DOI: 10.1016/j.idc.2018.04.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
130 Greenhalgh D, Al‐rashidi N. Modeling the spread of hepatitis C virus amongst people who inject drugs. Engineering Reports. [DOI: 10.1002/eng2.12503] [Reference Citation Analysis]
131 Assih M, Ouattara AK, Diarra B, Yonli AT, Compaore TR, Obiri-Yeboah D, Djigma FW, Karou S, Simpore J. Genetic diversity of hepatitis viruses in West-African countries from 1996 to 2018. World J Hepatol 2018; 10(11): 807-821 [PMID: 30533182 DOI: 10.4254/wjh.v10.i11.807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
132 Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines (Basel) 2020;8:E90. [PMID: 32079254 DOI: 10.3390/vaccines8010090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
133 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Reference Citation Analysis]
134 Hagag RS, Fakhry MM, Ahmed OA, Abdalgeleel SA, Radwan MA, Naguib GG. Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study. Egypt J Intern Med 2022;34. [DOI: 10.1186/s43162-022-00126-8] [Reference Citation Analysis]
135 Li L, Jiang X, Fu L, Zhang L, Feng Y. Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis. Clin Exp Med 2022. [PMID: 35499793 DOI: 10.1007/s10238-022-00827-y] [Reference Citation Analysis]
136 Okafor EN, Okonkwo IN, Ugonabo MC, Chukwukelu EE, Odurukwe OU, Osiri SN. Emerging risk factors associated with prevalence of hepatitis c virus infection among Nigerians: Findings from blood donors in an academic hospital, Enugu South-Eastern Nigeria. Int J Clin Pract 2020;74:e13460. [PMID: 31821702 DOI: 10.1111/ijcp.13460] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Lo Menzo S, Biagi E, Di Nuzzo M, Grilli A, Contini C. SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient. Ann Hepatol 2018;17:661-4. [PMID: 29893709 DOI: 10.5604/01.3001.0012.0950] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
138 Manuc D, Preda CM, Sandra I, Baicus C, Cerban R, Constantinescu I, Olteanu AO, Ciora CA, Manuc T, Chiriac DE, Chifulescu AE, Diculescu M, Tieranu C, Negreanu L, Oprea-Calin G, Manuc M. Signification of Serum Alpha-Fetoprotein Levels in Cases of Compensated Cirrhosis and Hepatitis C Virus without Hepatocellular Carcinoma. J Med Life 2020;13:68-74. [PMID: 32341704 DOI: 10.25122/jml-2019-0076] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018;6:79-84. [PMID: 29607308 DOI: 10.14218/jcth.2017.00067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
140 Vetter BN, Reipold EI, Ongarello S, Fajardo E, Tyshkovskiy A, Ben I, Vasylyev M. Prospective evaluation of hepatitis C virus antibody detection in whole blood collected on dried blood spots with the INNOTEST® HCV Ab IV enzyme immunoassay. J Clin Virol 2021;137:104783. [PMID: 33711695 DOI: 10.1016/j.jcv.2021.104783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Ismail F, Haq S, El-Garawani I, Abdelsameea E. Hepatitis C Virus Infection in Eastern Libya: Efforts Needed to Improve HCV Testing and Linkage to Care in the Resource-Limited Setting. Trop Med Infect Dis 2022;7:14. [PMID: 35202210 DOI: 10.3390/tropicalmed7020014] [Reference Citation Analysis]
142 Rodgers MA, Olivo A, Harris B, Lark C, Luo X, Berg MG, Meyer TV, Mohaimani A, Orf GS, Goldstein Y, Fox AS, Hirschhorn J, Glen WB, Nolte F, Landay A, Jennings C, Moy J, Servellita V, Chiu C, Batra R, Snell LB, Nebbia G, Douthwaite S, Tanuri A, Singh L, de Oliveira T, Ahouidi A, Mboup S, Cloherty GA. Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests. Journal of Clinical Virology 2022. [DOI: 10.1016/j.jcv.2022.105080] [Reference Citation Analysis]
143 Gutwerk A, Wex T, Stein K, Langner C, Canbay A, Malfertheiner P, Link A. Helicobacter Pylori Serology in Relation to Hepatitis C Virus Infection and IL28B Single Nucleotide Polymorphism. J Clin Med 2018;7:E44. [PMID: 29510558 DOI: 10.3390/jcm7030044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J. 2018;12:26-32. [PMID: 29541276 DOI: 10.2174/1874357901812010026] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 21.0] [Reference Citation Analysis]
145 Gander S, Morris A, Materniak S. An Evaluation of Hepatitis C Screening in Infants and Children Born to Seropositive Mothers in Saint John, New Brunswick. Cureus 2021;13:e17377. [PMID: 34584787 DOI: 10.7759/cureus.17377] [Reference Citation Analysis]
146 Isac T, Isac S, Ioanitescu S, Mihaly E, Tanasescu MD, Balan DG, Tulin A, Iliescu L. Dynamics of serum α-fetoprotein in viral hepatitis C without hepatocellular carcinoma. Exp Ther Med 2021;22:749. [PMID: 34035846 DOI: 10.3892/etm.2021.10181] [Reference Citation Analysis]
147 Silva CMD, Peder LD, Thomazella MV, Teixeira JJV, Bertolini DA. PROFILE OF HCV GENOTYPES AND HIV-SUBTYPES AMONG HIV-COINFECTED PATIENTS IN SOUTHERN BRAZIL. Arq Gastroenterol 2019;56:344-50. [PMID: 31800733 DOI: 10.1590/S0004-2803.201900000-68] [Reference Citation Analysis]
148 Kwon JC, Chang HY, Kwon OY, Park JH, Oh IS, Kim HJ, Lee JH, Roh HJ, Lee HW. Seroepidemiology of Hepatitis Viruses and Hepatitis B Genotypes of Female Marriage Immigrants in Korea. Yonsei Med J 2018;59:1072-8. [PMID: 30328322 DOI: 10.3349/ymj.2018.59.9.1072] [Reference Citation Analysis]
149 Butt N, Anoshia, Khan MA, Akbar A. Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi. Pak J Med Sci 2021;37:2014-9. [PMID: 34912436 DOI: 10.12669/pjms.37.7.4627] [Reference Citation Analysis]
150 de Ruiter PE, Gadjradj Y, de Knegt RJ, Metselaar HJ, Ijzermans JN, van der Laan LJ. Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid. World J Transplantation 2018; 8(5): 156-166 [PMID: 30211024 DOI: 10.5500/wjt.v8.i5.156] [Reference Citation Analysis]
151 Eloumou SAFB, Mefo'o JPN, Nga WTB, Kenfack GU, Yakana L, Malongue A, Okalla C, Kowo M, Andoulo FA, Tzeuton C, Bidja MSD, Namme HL, Adiogo D, Noah DN. [Cryoglobulin and factors associated with it in patient with anti-hepatitis-C antibodies living in resource-limited countries]. Pan Afr Med J 2019;33:169. [PMID: 31565130 DOI: 10.11604/pamj.2019.33.169.19162] [Reference Citation Analysis]
152 Huang J, Lok V, Ngai CH, Chu C, Patel HK, Thoguluva Chandraseka V, Zhang L, Chen P, Wang S, Lao XQ, Tse LA, Xu W, Zheng ZJ, Wong MCS. Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis. Liver Cancer 2021;10:330-45. [PMID: 34414121 DOI: 10.1159/000515304] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
153 Tatar M, Keeshin SW, Mailliard M, Wilson FA. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States. JAMA Netw Open 2020;3:e2015756. [PMID: 32880650 DOI: 10.1001/jamanetworkopen.2020.15756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
154 Motawi TMK, Sabry D, Shehata NI, William MM, Fahim AT. Impact of FOXP1 rs2687201 genetic variant on the susceptibility to HCV-related hepatocellular carcinoma in Egyptians. J Biochem Mol Toxicol 2021;:e22965. [PMID: 34783112 DOI: 10.1002/jbt.22965] [Reference Citation Analysis]
155 Conti M, Matulli Cavedagna T, Ramazzotti E, Mancini R, Calza L, Rinaldi M, Badia L, Guardigni V, Viale P, Verucchi G. Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS. Clinical Mass Spectrometry 2018;7:6-17. [DOI: 10.1016/j.clinms.2017.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
156 de Bitencorte JT, Rech TF, Lunge VR, dos Santos DC, Álvares-da-Silva MR, Simon D. Association of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection. World J Hepatol 2021; 13(1): 109-119 [PMID: 33584990 DOI: 10.4254/wjh.v13.i1.109] [Reference Citation Analysis]
157 Abdel-Al A, El-Ahwany E, Zoheiry M, Hassan M, Ouf A, Abu-Taleb H, Abdel Rahim A, El-Talkawy MD, Zada S. miRNA-221 and miRNA-222 are promising biomarkers for progression of liver fibrosis in HCV Egyptian patients. Virus Res 2018;253:135-9. [PMID: 29932949 DOI: 10.1016/j.virusres.2018.06.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
158 Han B, Zheng Y, Wang L, Wang H, Du J, Ye F, Sun T, Zhang L. A novel microRNA signature predicts vascular invasion in hepatocellular carcinoma. J Cell Physiol 2019;234:20859-68. [PMID: 30997686 DOI: 10.1002/jcp.28690] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
159 Trickey A, Fraser H, Lim AG, Walker JG, Peacock A, Colledge S, Leung J, Grebely J, Larney S, Martin NK, Degenhardt L, Hickman M, May MT, Vickerman P. Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. J Viral Hepat 2019;26:1388-403. [PMID: 31392812 DOI: 10.1111/jvh.13187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
160 Jothimani D, Venugopal R, Vij M, Rela M. Post liver transplant recurrent and de novo viral infections. Best Pract Res Clin Gastroenterol. 2020;46-47:101689. [PMID: 33158469 DOI: 10.1016/j.bpg.2020.101689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
161 Wang YW, Lee WP, Huang YH, Hou MC, Lan KH. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. BMC Infect Dis 2021;21:984. [PMID: 34548026 DOI: 10.1186/s12879-021-06657-9] [Reference Citation Analysis]
162 Mahmoudvand S, Shokri S, Azaran A, Seyedian SS, Makvandi M, Mirzaei H, Sheikhrobat SB. Seronegative occult hepatitis C infection among hemodialysis patients: A prevalence study. Ther Apher Dial 2021;25:218-24. [PMID: 32510846 DOI: 10.1111/1744-9987.13535] [Reference Citation Analysis]
163 Possuelo LG, Perin D, Breunig PF, Schroeder DF, Allgayer MF, Darsie C, Carneiro M, Hermes V, Renner JDP. Hepatitis C: evaluation of outcomes and georeferencing of cases in Santa Cruz do Sul, Brazil, between 2002 and 2015. A cross-sectional study. Sao Paulo Med J 2018;136:109-15. [PMID: 29267536 DOI: 10.1590/1516-3180.2017.0169180917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
164 Guedes de Sá KS, Amoras EDSG, Conde SRSDS, Queiroz MAF, Cayres-Vallinoto IMV, Ishak R, Vallinoto ACR. Intrahepatic TLR3 and IFNL3 Expressions Are Associated with Stages of Fibrosis in Chronic Hepatitis C. Viruses 2021;13:1103. [PMID: 34207750 DOI: 10.3390/v13061103] [Reference Citation Analysis]
165 Jia B, Wang Y, Yu G, Cheng Y, Yang C, Cao F, He Y, Cao P, Meng X, Yu D. Naringenin ameliorates insulin resistance by modulating endoplasmic reticulum stress in hepatitis C virus-infected liver. Biomed Pharmacother 2019;115:108848. [PMID: 31039496 DOI: 10.1016/j.biopha.2019.108848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
166 Liu B, Gai K, Qin H, Liu X, Cao Y, Lu Q, Lu D, Chen D, Shen H, Song W, Zhang Y, Wang X, Xu H, Zhang Y. Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity. Eur J Med Chem 2018;148:95-105. [PMID: 29454920 DOI: 10.1016/j.ejmech.2018.02.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
167 Younossi ZM, Henry L, P. Ong J, Tanaka A, Eguchi Y, Mizokami M, Lim Y, Dan YY, Yu M, Stepanova M. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Aliment Pharmacol Ther 2019;49:644-53. [DOI: 10.1111/apt.15131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
168 Alduraywish A, Ragheb M, Taher I, Louis N, Aldossari K, Kishk R. Prevalence, risk factors and impact of occult HCV infection on liver morbidity among haemodialysis patients: hospital-based cross-sectional study. Scand J Gastroenterol 2020;55:963-9. [PMID: 32649843 DOI: 10.1080/00365521.2020.1790649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
169 Powell D, Alpert A, Pacula RL. A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C. Health Aff (Millwood) 2019;38:287-94. [PMID: 30715966 DOI: 10.1377/hlthaff.2018.05232] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
170 Bricks G, Senise JF, Pott Junior H, Grandi G, Passarini A, Caldeira DB, Carnaúba Junior D, Moraes HAB, Granato CFH, Castelo A. Seroprevalence of hepatitis E virus in chronic hepatitis C in Brazil. Braz J Infect Dis 2018;22:85-91. [PMID: 29494796 DOI: 10.1016/j.bjid.2018.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
171 Arafa A, Eshak ES, Abdel Rahman TA, Anwar MM. Hepatitis C virus infection and risk of pancreatic cancer: A meta-analysis. Cancer Epidemiol 2020;65:101691. [PMID: 32088651 DOI: 10.1016/j.canep.2020.101691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
172 Oliveira ÍMX, Silva RDSUD. Rheumatological Manifestations Associated with Viral Hepatitis B or C. Rev Soc Bras Med Trop 2019;52:e20180407. [PMID: 31800917 DOI: 10.1590/0037-8682-0407-2018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
173 Lu Y, Jin X, Duan C, Chang F, Khudyakov YE. Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China. PLoS ONE 2018;13:e0195117. [DOI: 10.1371/journal.pone.0195117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
174 Minme R, Holzmann I, Tovo CV, Almeida PRL. PROFILE OF PATIENTS WITH CHRONIC HEPATITIS C IN A PUBLIC HEALTH PROGRAM IN SOUTHERN BRAZIL. Arq Gastroenterol 2018;55:403-6. [PMID: 30785526 DOI: 10.1590/S0004-2803.201800000-86] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
175 Afifi MAE, Hussein AM, Rizk M. Low Serum 25-Hydroxy Vitamin D (25-OHD) and Hepatic Encephalopathy in HCV-Related Liver Cirrhosis. Int J Hepatol 2021;2021:6669527. [PMID: 33628512 DOI: 10.1155/2021/6669527] [Reference Citation Analysis]
176 Haqqi A, Munir R, Khalid M, Khurram M, Zaid M, Ali M, Shah ZH, Ahmed H, Afzal MS. Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature. Viral Immunol 2019;32:402-13. [PMID: 31556811 DOI: 10.1089/vim.2019.0058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
177 Sood A, Suryaprasad A, Trickey A, Kanchi S, Midha V, Foster MA, Bennett E, Kamili S, Alvarez-Bognar F, Shadaker S, Surlikar V, Garg R, Mittal P, Sharma S, May MT, Vickerman P, Averhoff F. The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey. PLoS One 2018;13:e0200461. [PMID: 30048454 DOI: 10.1371/journal.pone.0200461] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
178 Moran CA, Collins LF, Beydoun N, Mehta PK, Fatade Y, Isiadinso I, Lewis TT, Weber B, Goldstein J, Ofotokun I, Quyyumi A, Choi MY, Titanji K, Lahiri CD. Cardiovascular Implications of Immune Disorders in Women. Circ Res 2022;130:593-610. [PMID: 35175848 DOI: 10.1161/CIRCRESAHA.121.319877] [Reference Citation Analysis]
179 Nejabat N, Hosseini SY, Sarvari J, Gorzin AA, Fattahi MR, Rasoolian M. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients. Asian Pac J Cancer Prev 2019;20:2311-7. [PMID: 31450900 DOI: 10.31557/APJCP.2019.20.8.2311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
180 Geenen JW, Boersma C, Klungel OH, Hövels AM. Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. Eur J Health Econ 2019;20:857-67. [PMID: 30953216 DOI: 10.1007/s10198-019-01048-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
181 Younossi ZM, Stepanova M, Henry L, Han KH, Ahn SH, Lim YS, Chuang WL, Kao JH, Nguyen KV, Lai CL, Chan HL, Wei L. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. J Viral Hepat. 2018;25:1429-1437. [PMID: 29974665 DOI: 10.1111/jvh.12965] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
182 Elzouki AN, Lubbad R, Elzouki I, Elhaddad A, Ibrahim A. Frequency of hepatitis B and C in health care providers at three referral hospitals in Libya. Pan Afr Med J 2020;37:214. [PMID: 33520053 DOI: 10.11604/pamj.2020.37.214.23997] [Reference Citation Analysis]
183 Tan YW, Tao Y, Liu LG, Ye Y, Zhou XB, Chen L, He C. Epidemiological features of chronic hepatitis C infection caused by remunerated blood donors: A nearly 27-year period survey. World J Gastroenterol 2018; 24(11): 1250-1258 [PMID: 29568205 DOI: 10.3748/wjg.v24.i11.1250] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
184 Feleke BE, Feleke TE, Adane WG, Girma A. Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study. Virol J 2020;17:113. [PMID: 32703225 DOI: 10.1186/s12985-020-01385-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Miarons M, Sánchez-Ulayar A, Sempere G, Marín S, Castellví JM. New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups. Eur J Hosp Pharm 2019;26:135-9. [PMID: 31428320 DOI: 10.1136/ejhpharm-2017-001352] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
186 Jothimani D, Danielraj S, Narasimhan G, Kaliamoorthy I, Rajakumar A, Palaniappan K, Palanichamy S, Rammohan A, Ramachandran H, Rajalingam R, Rela M. Nonalcoholic Steatohepatitis: A Rapidly Increasing Indication for Liver Transplantation in India. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.09.017] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
187 Wei L, Wang G, Alami NN, Xie W, Heo J, Xie Q, Zhang M, Kim YJ, Lim SG, Fredrick LM, Lu W, Liu W, Kalluri HV, Krishnan P, Tripathi R, Mobashery N, Burroughs M, Asatryan A, Jia J, Hou J. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol. 2020;5:839-849. [PMID: 32682494 DOI: 10.1016/s2468-1253(20)30086-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
188 Vázquez-Morón S, Ardizone Jiménez B, Jiménez-Sousa MA, Bellón JM, Ryan P, Resino S. Evaluation of the diagnostic accuracy of laboratory-based screening for hepatitis C in dried blood spot samples: A systematic review and meta-analysis. Sci Rep 2019;9:7316. [PMID: 31086259 DOI: 10.1038/s41598-019-41139-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
189 Wing PAC, Jones M, Cheung M, DaSilva S, Bamford C, Jason Lee WY, Aranday-Cortes E, Da Silva Filipe A, McLauchlan J, Smith D, Irving W, Cunningham M, Ansari A, Barnes E, Foster GR. Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. Gastroenterology 2019;157:692-704.e9. [PMID: 31078622 DOI: 10.1053/j.gastro.2019.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
190 Losurdo G, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C. Diagnostics (Basel). 2020;10. [PMID: 33276638 DOI: 10.3390/diagnostics10121037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 Malebranche M, King D, Leonard J. Descriptive epidemiology of hepatitis C in individuals referred for specialized HCV care in Newfoundland and Labrador, 1996–2014. CanLivJ 2018;1:107-14. [DOI: 10.3138/canlivj.2018-0013] [Reference Citation Analysis]
192 Huang P, Wang CH, Zhuo LY, Xia XS, Yang S, Zhang JW, Fan HZ, Wu JJ, Yu R, Yue M, Zhang Y. Polymorphisms rs763110 in FASL is linked to hepatitis C virus infection among high-risk populations. Br J Biomed Sci 2020;77:112-7. [PMID: 32209020 DOI: 10.1080/09674845.2020.1747182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
193 Mesalam AA, Desombere I, Farhoudi A, Van Houtte F, Verhoye L, Ball J, Dubuisson J, Foung SKH, Patel AH, Persson MAA, Leroux-Roels G, Meuleman P. Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1. Virology 2018;514:30-41. [PMID: 29128754 DOI: 10.1016/j.virol.2017.10.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
194 Bhattacharjee C, Singh M, Das D, Chaudhuri S, Mukhopadhyay A. Current therapeutics against HCV. Virusdisease 2021;:1-16. [PMID: 34307769 DOI: 10.1007/s13337-021-00697-0] [Reference Citation Analysis]
195 Nardelli S, Riggio O, Rosati D, Gioia S, Farcomeni A, Ridola L. Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms. World J Gastroenterol 2019; 25(48): 6928-6938 [PMID: 31908396 DOI: 10.3748/wjg.v25.i48.6928] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
196 Shakeri A, Srimurugathasan N, Suda KJ, Gomes T, Tadrous M. Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. Value Health 2020;23:1137-41. [PMID: 32940230 DOI: 10.1016/j.jval.2020.03.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
197 Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018;68:1298-1307. [PMID: 29672891 DOI: 10.1002/hep.30046] [Cited by in Crossref: 105] [Cited by in F6Publishing: 87] [Article Influence: 26.3] [Reference Citation Analysis]
198 Naghipour-khalkhaliani D, Behzadpour D, Mousavi Nasab SD. Distribution of Hepatitis C Virus Genotypes in Rasht, Capital City of Guilan Province, Northern Part of Iran. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.62030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
199 Gaafar AE, Abd El-Aal A, Alboraie M, Hassan HM, ElTahan A, AbdelRahman Y, Wifi MN, Omran D, Mansour SA, Hassan WM, Ismail M, El Kassas M. Prevalence of prolonged QT interval in patients with HCV-related chronic liver disease. Egypt Heart J 2019;71:15. [PMID: 31659581 DOI: 10.1186/s43044-019-0016-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
200 Chouikha A, Khedhiri M, Triki H, Hammemi W, Sadraoui A, Touzi H, Ben Yahia A, Chtourou A, Gargouri S, Feki Ben Rajah L, Hakim Karray H, Triki H. Focus on hepatitis C virus genotype distribution in Tunisia prior to elimination: a 16-year retrospective study. Arch Virol 2021;166:501-10. [PMID: 33394169 DOI: 10.1007/s00705-020-04918-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Akiyama MJ, Muller A, Huang O, Lizcano J, Nyakowa M, Riback L, Ross J, Bundi H, Kulabi ES, Mwangi AM, Musyoki H, Cherutich P, Kurth A. Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study. Glob Public Health 2021;:1-13. [PMID: 33689563 DOI: 10.1080/17441692.2021.1896763] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
202 Irshad M, Gupta P, Irshad K. Immunopathogenesis of Liver Injury During Hepatitis C Virus Infection. Viral Immunol 2019;32:112-20. [PMID: 30817236 DOI: 10.1089/vim.2018.0124] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
203 Jekarl DW, Choi H, Lee S, Kwon JH, Lee SW, Yu H, Kim M, Kim Y, Sung PS, Yoon SK. Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) Among Chronic Hepatitis B Patients. Ann Lab Med. 2018;38:348-354. [PMID: 29611385 DOI: 10.3343/alm.2018.38.4.348] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
204 Fukui A, Kawabe N, Hashimoto S, Kamei H, Yoshioka K. Skeletal muscle mass depletion in patients with hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2019;31:59-66. [PMID: 30179904 DOI: 10.1097/meg.0000000000001255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 Zhao Q, Jiang S, Li M, Yao L, Ma X, Li M, Wang C, Pan Y, Zhao H, Li B. Incidence trend and age-period-cohort analysis of reported hepatitis C among residents aged 30 to 79 in northeastern China, 2008 to 2017. Medicine (Baltimore) 2020;99:e22005. [PMID: 32899048 DOI: 10.1097/MD.0000000000022005] [Reference Citation Analysis]
206 Kwon JW, Tchoe HJ, Lee J, Suh JK, Lee JH, Shin S. The Impact of National Surveillance for Liver Cancer: Results from Real-World Setting in Korea. Gut Liver 2020;14:108-16. [PMID: 30974929 DOI: 10.5009/gnl18522] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
207 Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT;  IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
208 Asahina Y, Liu CJ, Gane E, Itoh Y, Kawada N, Ueno Y, Youn J, Wang CY, Llewellyn J, Matsuda T, Gaggar A, Mo H, Dvory-Sobol H, Crans G, Chuang WL, Chen PJ, Enomoto N. Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. Hepatol Res 2020;50:1109-17. [PMID: 32614468 DOI: 10.1111/hepr.13546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
209 Castro VOL, Kamili S, Forbi JC, Stabile AC, da Silva EF, do Valle Leone de Oliveira SM, de Carvalho PRT, Puga MAM, Tanaka TSO, do Lago BV, Ibanhes ML, Araujo A, Tejada-Strop A, Lin Y, Xia GL, Sue A, Teles SA, Motta-Castro ARC. High prevalence of Hepatitis C Virus infection among people who use crack cocaine in an important international drug trafficking route in Central-West Region Brazil. Infect Genet Evol 2020;85:104488. [PMID: 32745809 DOI: 10.1016/j.meegid.2020.104488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
210 Chiu YL, Lin HC, Kuo NW, Kao S, Lee HC. Increased risk of concurrent hepatitis C among Male patients with schizophrenia. Psychiatry Res 2017;258:217-20. [PMID: 28844561 DOI: 10.1016/j.psychres.2017.08.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
211 Coleman WB, Tsongalis GJ. Understanding molecular pathogenesis: the biological basis of human disease and implications for improved treatment of human disease. Essential Concepts in Molecular Pathology. Elsevier; 2020. pp. 191-200. [DOI: 10.1016/b978-0-12-813257-9.00012-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
212 Gálvez JA, Clavería-gimeno R, Galano-frutos JJ, Sancho J, Velázquez-campoy A, Abian O, Díaz-de-villegas MD. Stereoselective synthesis and biological evaluation as inhibitors of hepatitis C virus RNA polymerase of GSK3082 analogues with structural diversity at the 5-position. European Journal of Medicinal Chemistry 2019;171:401-19. [DOI: 10.1016/j.ejmech.2019.03.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
213 Mahmud S, Kouyoumjian SP, Al Kanaani Z, Chemaitelly H, Abu-Raddad LJ. Individual-level key associations and modes of exposure for hepatitis C virus infection in the Middle East and North Africa: a systematic synthesis. Ann Epidemiol 2018;28:452-61. [PMID: 29661680 DOI: 10.1016/j.annepidem.2018.03.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
214 Makuza JD, Liu CY, Ntihabose CK, Dushimiyimana D, Umuraza S, Nisingizwe MP, Umutesi J, Serumondo J, Mugeni SD, Semakula M, Gupta N, Hellard M, Nsanzimana S. Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program. BMC Infect Dis 2019;19:688. [PMID: 31382901 DOI: 10.1186/s12879-019-4322-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
215 Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
216 Barkhash AV, Kochneva GV, Chub EV, Romaschenko AG. Single nucleotide polymorphism rs1800872 in the promoter region of the IL10 gene is associated with predisposition to chronic hepatitis C in Russian population. Microbes Infect 2018;20:212-6. [PMID: 29247709 DOI: 10.1016/j.micinf.2017.11.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
217 Atapour A, Mokarram P, Mostafavipour Z, Hosseini SY, Ghasemi Y, Mohammadi S, Nezafat N. Designing a Fusion Protein Vaccine Against HCV: An In Silico Approach. Int J Pept Res Ther 2019;25:861-72. [DOI: 10.1007/s10989-018-9735-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
218 Bulut ME, Topalca US, Murat A, Teke L, Canalp HZ, Ocal M, Bayraktar B. HCV Genotype Distribution of Patients with Chronic Hepatitis C in Istanbul. Sisli Etfal Hastan Tip Bul 2021;55:86-92. [PMID: 33935541 DOI: 10.14744/SEMB.2020.66990] [Reference Citation Analysis]
219 Agrawal B, Singh S, Gupta N, Li W, Vedi S, Kumar R. Unsolved Puzzles Surrounding HCV Immunity: Heterologous Immunity Adds Another Dimension. Int J Mol Sci 2017;18:E1626. [PMID: 28749434 DOI: 10.3390/ijms18081626] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
220 Elalfy H, Besheer T, El-maksoud M, Farid K, Elegezy M, El Nakib A, El-aziz M, El-khalek A, El-morsy A, Elmokadem A, Elsamanoudy A, El-bendary M. Monocyte/granulocyte to lymphocyte ratio and the MELD score as predictors for early recurrence of hepatocellular carcinoma after trans-arterial chemoembolization. British Journal of Biomedical Science 2018;75:187-91. [DOI: 10.1080/09674845.2018.1494769] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
221 Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
222 Lang Y, Li F, Liu Q, Xia Z, Ji Z, Hu J, Cheng Y, Gao M, Sun F, Shen B, Xie C, Yi W, Wu Y, Yao J, Cao Z. The Kv1.3 ion channel acts as a host factor restricting viral entry. FASEB J 2021;35:e20995. [PMID: 32910509 DOI: 10.1096/fj.202000879RR] [Reference Citation Analysis]
223 Bhagat N, Verma N, Singh V. HCC prediction post SVR in HCV patients: many tools yet limited generalizability! Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.04.028] [Reference Citation Analysis]
224 Okada M, Hai H, Tamori A, Uchida-Kobayashi S, Enomoto M, Kumada H, Kawada N. Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus. Clin J Gastroenterol 2019;12:213-7. [PMID: 30446954 DOI: 10.1007/s12328-018-0922-9] [Reference Citation Analysis]
225 Xie LT, Yan CH, Zhao QY, He MN, Jiang TA. Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography. World J Gastroenterol 2018; 24(9): 957-970 [PMID: 29531460 DOI: 10.3748/wjg.v24.i9.957] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
226 Tran L, Nhu Y M, Le Ba Nghia T, Hendam A, Vuong NL, Alzalal E, Sayed AM, Hussain MM, Sharma A, Tieu T, Mathenge PG, Hirayama K, Alexander N, Huy NT. Frequent inappropriate use of unweighted summary statistics in systematic reviews of pathogen genotypes or genogroups. J Clin Epidemiol 2020;119:26-35. [PMID: 31740320 DOI: 10.1016/j.jclinepi.2019.11.009] [Reference Citation Analysis]
227 Wong WW, Wong J, Bremner KE, Saeed Y, Mason K, Phoon A, Feng Z, Feld JJ, Mitsakakis N, Powis J, Krahn M. Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System. Value in Health 2022;25:247-56. [DOI: 10.1016/j.jval.2021.08.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Hutton J, Doyle J, Zordan R, Weiland T, Cocco A, Howell J, Iser S, Snell J, Fry S, New K, Sloane R, Jarman M, Phan D, Tran S, Pedrana A, Williams B, Johnson J, Glasgow S, Thompson A. Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department. Int J Drug Policy. 2019;72:84-90. [PMID: 31351752 DOI: 10.1016/j.drugpo.2019.06.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
229 Nabeel MM, Darwish RK, Alakel W, Maher R, Mostafa H, Hashem A, Elbeshlawy M, Abul-fotouh A, Shousha HI, Saeed Marie M. Changes in Serum Interferon Gamma and Interleukin-10 in Relation to Direct-Acting Antiviral Therapy of Chronic Hepatitis C Genotype 4: A Pilot Study. Journal of Clinical and Experimental Hepatology 2022;12:428-34. [DOI: 10.1016/j.jceh.2021.06.018] [Reference Citation Analysis]
230 Demsiss W, Seid A, Fiseha T. Hepatitis B and C: Seroprevalence, knowledge, practice and associated factors among medicine and health science students in Northeast Ethiopia. PLoS One 2018;13:e0196539. [PMID: 29763447 DOI: 10.1371/journal.pone.0196539] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
231 Çetin Duran A, Kaya Çetinkaya Ö, Sayıner AA, Şeydaoğlu G, Özkarataş E, Abacıoğlu H. Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol 2020;31:128-35. [PMID: 32141821 DOI: 10.5152/tjg.2020.18798] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
232 Skladaný L, Oltman M, Fraňková S, Dražilová S, Husa P, Šperl J, Hejda V, Urbánek P, Adamcová-Selčanová S, Janičko M, Kristian P, Kupčová V, Rác M, Schréter I, Virág L, Liptáková A, Ondrášová M, Jarčuška P. Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. Int J Public Health 2020;65:1723-35. [PMID: 33040165 DOI: 10.1007/s00038-020-01496-y] [Reference Citation Analysis]
233 Pott H, Bricks G, Senise JF, Castelo A. Chronic alcohol abuse and spontaneous clearance of hepatitis C virus. IDCases 2019;17:e00534. [PMID: 31384553 DOI: 10.1016/j.idcr.2019.e00534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
234 Yang X, Ding T, Huang H, Xu Y, Yu J, Chen Z. Development and validation of a simple and rapid method for hepatitis C virus genotyping based on one-step RT-qPCR. Exp Ther Med 2020;20:2284-90. [PMID: 32765706 DOI: 10.3892/etm.2020.8912] [Reference Citation Analysis]
235 Granados-García V, Flores YN, Díaz-Trejo LI, Méndez-Sánchez L, Liu S, Salinas-Escudero G, Toledano-Toledano F, Salmerón J. Estimating the prevalence of hepatitis C among intravenous drug users in upper middle income countries: A systematic review and meta-analysis. PLoS One 2019;14:e0212558. [PMID: 30807590 DOI: 10.1371/journal.pone.0212558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
236 Adadi A, Adadi S, Berrada M. Gastroenterology Meets Machine Learning: Status Quo and Quo Vadis. Adv Bioinformatics. 2019;2019:1870975. [PMID: 31065266 DOI: 10.1155/2019/1870975] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
237 Ghasemi A, Zadsar M, Shaiegan M, Samiei S, Namvar A, Rasouli M, Moosanejad M. Human platelet antigens polymorphisms; association to the development of liver fibrosis in patients with chronic hepatitis C. J Med Virol 2020;92:45-52. [PMID: 30729550 DOI: 10.1002/jmv.25423] [Reference Citation Analysis]
238 Catania VE, Malaguarnera G, Fiorenza G, Chisari EM, Lipari AR, Gallina V, Pennisi M, Lanza G, Malaguarnera M. Hepatitis C Virus Infection Increases Fatigue in Health Care Workers. Diseases 2020;8:E37. [PMID: 33076215 DOI: 10.3390/diseases8040037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
239 Kamhawy A, Ahmed Said ZN, Abdelhamid SE, El-Sayed M, Eletreby R, Garem HE, El Kassas M, Esmat G. Hepatitis C viral RNA in blood mononuclear cells of patients treated with directly acting antivirals. Arab J Gastroenterol 2021;22:158-63. [PMID: 33820724 DOI: 10.1016/j.ajg.2021.03.001] [Reference Citation Analysis]
240 Nguyen E, Trinh S, Trinh H, Nguyen H, Nguyen K, Do A, Levitt B, Do S, Nguyen M, Purohit T, Shieh E, Nguyen MH. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. Aliment Pharmacol Ther. 2019;49:99-106. [PMID: 30467877 DOI: 10.1111/apt.15043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
241 Ely A, Singh P, Smith TS, Arbuthnot P. In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection. Adv Drug Deliv Rev. 2021;168:134-146. [PMID: 32485207 DOI: 10.1016/j.addr.2020.05.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
242 Coppola N, Alessio L, Onorato L, Sagnelli C, Macera M, Sagnelli E, Pisaturo M. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty 2019;8:17. [PMID: 30871599 DOI: 10.1186/s40249-019-0528-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
243 Ahmad S, Shahid F, Tahir Ul Qamar M, Rehman HU, Abbasi SW, Sajjad W, Ismail S, Alrumaihi F, Allemailem KS, Almatroudi A, Ullah Saeed HF. Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design. Vaccines (Basel) 2021;9:293. [PMID: 33801143 DOI: 10.3390/vaccines9030293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
244 Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther 2019;49:492-505. [PMID: 30687952 DOI: 10.1111/apt.15100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
245 Yamazaki K, Macaulay D, Song Y, Sanchez Gonzalez Y. Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data. Infect Dis Ther 2019;8:285-99. [PMID: 30771220 DOI: 10.1007/s40121-019-0234-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
246 Montasser MF, Zaky S, Salaheldin M, Johar D, Abushouk AI, El-Raey F, Al-Husseini M, Mohammed EG. Fib-4 Predicts Early Hematological Adverse Events Induced by Interferon-Based Triple Therapy in Chronic Hepatitis C Virus Patients. J Interferon Cytokine Res 2019;39:85-94. [PMID: 30657408 DOI: 10.1089/jir.2018.0131] [Reference Citation Analysis]
247 Hashem MB, Badary HA, Mahfouz NA, Adel S, Alboraie M, AbdAllah M, AlAkel W, Saeed R, Ammar I, Abdel-Razek W, Hassany M, Esmat G. Evaluation of factors affecting patients' refusal of HCV treatment in a cohort of Egyptian patients. J Public Health (Oxf) 2021:fdab363. [PMID: 34651189 DOI: 10.1093/pubmed/fdab363] [Reference Citation Analysis]
248 Maughan A, Ogbuagu O. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol 2018;14:219-27. [PMID: 29271660 DOI: 10.1080/17425255.2018.1421173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
249 Hussein NR, Saleema ZSM, Abd QH. Direct Acting Antiviral Treatment for Patients with End-Stage Kidney Disease with Acute HCV Infection. Mediterr J Hematol Infect Dis 2019;11:e2019034. [PMID: 31205638 DOI: 10.4084/MJHID.2019.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
250 Fernandes FF, Perazzo H, Andrade LE, Dellavance A, Terra C, Pereira G, Pereira JL, Campos F, Ferraz ML, Perez RM. Latent Class Analysis of Noninvasive Methods and Liver Biopsy in Chronic Hepatitis C: An Approach without a Gold Standard. Biomed Res Int 2017;2017:8252980. [PMID: 29057268 DOI: 10.1155/2017/8252980] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
251 Xu Y, Zuo W, Wang X, Zhang Q, Gan X, Tan N, Jia W, Liu J, Li Z, Zhou B, Zhao D, Xie Z, Tan Y, Zheng S, Liu C, Li H, Chen Z, Yang X, Huang Z. Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma. Int J Biol Sci 2021;17:2223-39. [PMID: 34239351 DOI: 10.7150/ijbs.58026] [Reference Citation Analysis]
252 Hassan AM, Osman HA, Mahmoud HS, Hassan MH, Hashim AA, Ameen HH. Sofosbuvir-daclatasvir improves hepatitis C virus-induced mixed cryoglobulinemia: Upper Egypt experience. Infect Drug Resist 2018;11:895-901. [PMID: 29983581 DOI: 10.2147/IDR.S167093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
253 Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, Leung J, Grebely J, Larney S, Martin NK, Hickman M, Degenhardt L, May MT, Vickerman P. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol 2019;4:435-44. [PMID: 30981685 DOI: 10.1016/S2468-1253(19)30085-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 23] [Article Influence: 17.3] [Reference Citation Analysis]
254 Ursu LD, Calenic B, Diculescu M, Dima A, Stoian IT, Constantinescu I. Clinical and histopathological changes in different KIR gene profiles in chronic HCV Romanian patients. Int J Immunogenet 2021;48:16-24. [PMID: 32961633 DOI: 10.1111/iji.12515] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
255 Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun. 2017;1:87-98. [PMID: 29404447 DOI: 10.1002/hep4.1028] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 8.6] [Reference Citation Analysis]
256 Santos M, Protopopescu C, Delarocque-Astagneau E, Bourlière M, Petrov-Sanchez V, Di Beo V, Larrey D, Baudoin M, Dorival C, Bureau M, Fontaine H, Carrat F, Marcellin F, Pol S, Carrieri P; ANRS CO22 HEPATHER study group. Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). Liver Int 2021. [PMID: 34520614 DOI: 10.1111/liv.15056] [Reference Citation Analysis]
257 Pitak-Arnnop P, Subbalekha K, Sirintawat N, Tangmanee C, Auychai P, Muangchan C, Sukphopetch P, Meningaud JP, Neff A. Are oral lichen planus patients at high risk of hepatitis C? A case-control study. J Stomatol Oral Maxillofac Surg 2021:S2468-7855(21)00159-2. [PMID: 34332181 DOI: 10.1016/j.jormas.2021.07.013] [Reference Citation Analysis]
258 Batsaikhan B, Lu MY, Yeh ML, Huang CI, Huang CF, Lin ZY, Chen SC, Huang JF, Hsieh PH, Chuang WL, Lee JC, Yu ML, Dai CY. Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis C. J Chin Med Assoc 2019;82:277-81. [PMID: 30946707 DOI: 10.1097/JCMA.0000000000000064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Puigvehí M, De Cuenca B, Viu A, Diago M, Turnes J, Gea F, Pascasio JM, Lens S, Cabezas J, Badia E, Olveira A, Morillas RM, Torras X, Montoliu S, Cordero P, Castro JL, Salmerón J, Molina E, Sánchez-Ruano JJ, Moreno J, Antón MD, Moreno JM, De la Vega J, Calleja JL, Carrión JA. Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort. Liver Int 2019;39:90-7. [PMID: 30160363 DOI: 10.1111/liv.13950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
260 Gadallah M, Kandil S, Mohsen A. Association between hepatitis C infection and cerebro-cardiovascular disease: analysis of a national population-based survey in Egypt. Trop Med Int Health 2018;23:738-47. [PMID: 29723920 DOI: 10.1111/tmi.13068] [Reference Citation Analysis]
261 Silbernagl M, Slamanig R, Fischer G, Brandt L. Hepatitis C infection and psychiatric burden in two imprisoned cohorts: Young offenders and opioid-maintained prisoners. Health Policy 2018;122:1392-402. [PMID: 30392782 DOI: 10.1016/j.healthpol.2018.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
262 Iliescu L, Mercan-Stanciu A, Toma L, Ioanitescu ES. A SEVERE CASE OF HYPERGLYCEMIA IN A KIDNEY TRANSPLANT RECIPIENT UNDERGOING INTERFERON-FREE THERAPY FOR CHRONIC HEPATITIS C. Acta Endocrinol (Buchar) 2018;14:533-8. [PMID: 31149309 DOI: 10.4183/aeb.2018.533] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
263 Chi X, Wang M, Pan Y, Jiang J, Jiang T, Yan H, Wu R, Wang X, Gao X, Niu J. Inosine triphosphate pyrophosphatase polymorphisms are predictors of anemia in Chinese patients with chronic hepatitis C during therapy with ribavirin and interferon. J Gastroenterol Hepatol 2020;35:97-103. [PMID: 31359493 DOI: 10.1111/jgh.14812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
264 Catania VE, Malaguarnera G, Fiorenza G, Chisari EM, Lipari AR, Gallina V, Pennisi M, Lanza G, Malaguarnera M. Hepatitis C Virus Infection Increases Fatigue in Health Care Workers. Diseases 2020;8:E37. [PMID: 33076215 DOI: 10.3390/diseases8040037] [Reference Citation Analysis]
265 Fathi H, Clark A, Hill NR, Dusheiko G. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review. BMC Infect Dis 2017;17:722. [PMID: 29145802 DOI: 10.1186/s12879-017-2820-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
266 Macek Jilkova Z, Saleem K, Afzal S, Decaens T. Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV. Livers 2021;1:313-21. [DOI: 10.3390/livers1040024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Rao H, Liu H, Wu E, Yang M, Feng B, Lin A, Fei R, Fontana RJ, Wei L, Lok AS. Comparison of clinical outcomes and impact of SVR in American and Chinese patients with chronic hepatitis C. JHEP Rep 2020;2:100136. [PMID: 32715286 DOI: 10.1016/j.jhepr.2020.100136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
269 Danilenko NG, Siniauskaya MG, Lukashyk SP, Karpov IA, Davydenko OG. “Double Punch”: Hepatitis C in Patients with Genetic Defects of Iron Metabolism. Cytol Genet 2019;53:407-17. [DOI: 10.3103/s0095452719050062] [Reference Citation Analysis]
270 Patra T, Ray RB, Ray R. Strategies to Circumvent Host Innate Immune Response by Hepatitis C Virus. Cells 2019;8:E274. [PMID: 30909456 DOI: 10.3390/cells8030274] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
271 Masrour-Roudsari J, Ebrahimpour S. Causal role of infectious agents in cancer: An overview. Caspian J Intern Med 2017;8:153-8. [PMID: 28932365 DOI: 10.22088/cjim.8.3.153] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
272 Pavicic Ivelja M, Dolic K, Tandara L, Perkovic N, Mestrovic A, Ivic I. Blood markers of endothelial dysfunction and their correlation to cerebrovascular reactivity in patients with chronic hepatitis C infection. PeerJ 2021;9:e10723. [PMID: 33520470 DOI: 10.7717/peerj.10723] [Reference Citation Analysis]
273 Ozakyol A. Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). J Gastrointest Cancer. 2017; Epub ahead of print. [PMID: 28626852 DOI: 10.1007/s12029-017-9959-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 14.0] [Reference Citation Analysis]
274 Estrada V, Sagastagoitia I. Hepatitis C is a risk factor for cardiovascular disease. Revista Clínica Española (English Edition) 2019;219:322-3. [DOI: 10.1016/j.rceng.2019.03.005] [Reference Citation Analysis]
275 Sho T, Suda G, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Izumi T, Kawagishi N, Baba M, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. Intern Med 2019;58:797-802. [PMID: 30449808 DOI: 10.2169/internalmedicine.1856-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
276 Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, McCubrey JA, Cervello M. GSK-3 in liver diseases: Friend or foe? Biochim Biophys Acta Mol Cell Res 2020;1867:118743. [PMID: 32417256 DOI: 10.1016/j.bbamcr.2020.118743] [Reference Citation Analysis]
277 Amirsardari Z, Rahmani F, Rezaei N. Cognitive impairments in HCV infection: From pathogenesis to neuroimaging. J Clin Exp Neuropsychol 2019;41:987-1000. [PMID: 31405320 DOI: 10.1080/13803395.2019.1652728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
278 Chang C, Hung CH, Wang JH, Lu SN. Hepatitis C core antigen highly correlated to HCV RNA. Kaohsiung J Med Sci 2018;34:684-8. [PMID: 30527202 DOI: 10.1016/j.kjms.2018.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
279 Agboghoroma CO, Ukaire BC. Prevalence and Risk Factors of Human Immunodeficiency Virus and Hepatitis C Virus Infection among Pregnant Women Attending Antenatal Care at a Tertiary Hospital in Abuja, Nigeria. Niger Med J 2020;61:245-51. [PMID: 33487847 DOI: 10.4103/nmj.NMJ_241_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
280 Uribe-Noguez LA, Ocaña-Mondragón A, Mata-Marín JA, Gómez-Torres ME, Ribas-Aparicio RM, de la Luz Martínez-Rodríguez M. Presence of rare hepatitis C virus subtypes, 2j, 2k, and 2r in Mexico City as identified by sequencing. J Med Virol 2018;90:1277-82. [PMID: 29508903 DOI: 10.1002/jmv.25070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
281 Yamamoto C, Nagashima S, Chuon C, Ko K, Huy Do S, Lim O, Hok S, Svay S, Matsuo J, Katayama K, Takahashi K, Tanaka J. Substitution of the CD81 Binding Site and β-Sandwich Area in E2 of HCV in Cambodia. Viruses 2020;12:E551. [PMID: 32429467 DOI: 10.3390/v12050551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
282 John M, Oommen S, Jagan OA, George S, Pillai S. A study on the circulating genotypes of hepatitis C virus in a tertiary care hospital in Central Kerala. Indian J Med Microbiol 2018;36:532-6. [PMID: 30880702 DOI: 10.4103/ijmm.IJMM_18_239] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
283 Abdel Ghaffar TY, El Naghi S, Abdel Gawad M, Helmy S, Abdel Ghaffar A, Yousef M, Moafy M. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4. J Viral Hepat. 2019;26:263-270. [PMID: 30380158 DOI: 10.1111/jvh.13032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
284 He N, Feng G, Hao S, Xu M, Liu J, Kong F, Ren Z, Gan H, Yao C, Liang T, Wang J. The Impact of Direct-Acting Antivirals on Quality of Life in Patients with Hepatitis C Virus Infection: a meta-analysis. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100705] [Reference Citation Analysis]
285 Danilescu CM, Sandulescu DL, Pirlog MC, Streba CT, Rogoveanu I. Depressive and Anxious Symptoms in Hepatitis C Virus Infected Patients Receiving DAA-Based Therapy. Diagnostics (Basel) 2021;11:2237. [PMID: 34943472 DOI: 10.3390/diagnostics11122237] [Reference Citation Analysis]
286 Li Z, Chen ZW, Li H, Ren H, Hu P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. Infect Drug Resist 2017;10:377-92. [PMID: 29184422 DOI: 10.2147/IDR.S146595] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
287 Colombo MG, Musabaev EI, Ismailov UY, Zaytsev IA, Nersesov AV, Anastasiy IA, Karpov IA, Golubovska OA, Kaliaskarova KS, AC R, Hadigal S. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World J Gastroenterol 2019; 25(29): 3897-3919 [PMID: 31413526 DOI: 10.3748/wjg.v25.i29.3897] [Reference Citation Analysis]
288 Kahyesh-Esfandiary R, Sadigh ZA, Esghaei M, Bastani MN, Donyavi T, Najafi A, Fakhim A, Bokharaei-Salim F. Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta-thalassemia major: Occult HCV infection. J Med Virol. 2019;91:107-114. [PMID: 30091793 DOI: 10.1002/jmv.25279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
289 Liu X, Duan X, Holmes JA, Li W, Lee SH, Tu Z, Zhu C, Salloum S, Lidofsky A, Schaefer EA, Cai D, Li S, Wang H, Huang Y, Zhao Y, Yu ML, Xu Z, Chen L, Hong J, Lin W, Chung RT. A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6. Hepatology 2019;69:1004-19. [PMID: 30199576 DOI: 10.1002/hep.30266] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
290 McPhee F, Ueland J, Vellucci V, Bowden S, Sievert W, Zhou N. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the In Vitro Potency of Direct-Acting Antiviral Agents. Antimicrob Agents Chemother 2019;63:e02205-18. [PMID: 30718256 DOI: 10.1128/AAC.02205-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
291 Ezat AA, Elshemey WM. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches. Life Sci 2019;217:176-84. [PMID: 30528183 DOI: 10.1016/j.lfs.2018.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
292 An T, Dean M, Flower R, Tatzenko T, Chan HT, Kiely P, Faddy HM. Understanding occult hepatitis C infection. Transfusion 2020;60:2144-52. [PMID: 33460181 DOI: 10.1111/trf.16006] [Reference Citation Analysis]
293 Kumar N, Prabhu SS, Monga I, Banerjee I. Influence of IL28B gene polymorphisms on PegINF-RBV-mediated HCV clearance in HIV-HCV co-infected patients: A meta-analysis. Meta Gene 2021;29:100909. [DOI: 10.1016/j.mgene.2021.100909] [Reference Citation Analysis]
294 Kirdar S, Aydin N, Tiryaki Y, Ertugrul B, Coskun A, Bilgen M. Dynamics of HCV epidemiology in Aydin province of Turkey and the associated factors. APMIS 2018;126:109-13. [PMID: 29271117 DOI: 10.1111/apm.12790] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
295 Shunmugam L, Ramharack P, Soliman MES. Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors. Protein J 2017;36:397-406. [PMID: 28815420 DOI: 10.1007/s10930-017-9736-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
296 Prouté M, Le Coeur S, Tiv MH, Dub T, Jongpaijitsakul P, Ratnamhin A, Angkurawaranon C, Aramrattana A, Lallemant M. Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs. BMC Public Health 2020;20:1450. [PMID: 32972359 DOI: 10.1186/s12889-020-09549-w] [Reference Citation Analysis]
297 Negash AA, Olson RM, Griffin S, Gale M Jr. Modulation of calcium signaling pathway by hepatitis C virus core protein stimulates NLRP3 inflammasome activation. PLoS Pathog. 2019;15:e1007593. [PMID: 30811485 DOI: 10.1371/journal.ppat.1007593] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
298 Pott H, Theodoro M, de Almeida Vespoli J, Senise JF, Castelo A. Mother-to-child transmission of hepatitis C virus. European Journal of Obstetrics & Gynecology and Reproductive Biology 2018;224:125-30. [DOI: 10.1016/j.ejogrb.2018.03.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
299 Aydin Y, Stephens CM, Chava S, Heidari Z, Panigrahi R, Williams DD, Wiltz K, Bell A, Wilson W, Reiss K, Dash S. Chaperone-Mediated Autophagy Promotes Beclin1 Degradation in Persistently Infected Hepatitis C Virus Cell Culture. Am J Pathol. 2018;188:2339-2355. [PMID: 30075149 DOI: 10.1016/j.ajpath.2018.06.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
300 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
301 Marquez LK, Cepeda JA, Bórquez A, Strathdee SA, Gonzalez-Zúñiga PE, Fleiz C, Rafful C, Garfein RS, Kiene SM, Brodine S, Martin NK. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. Int J Drug Policy 2021;88:102710. [PMID: 32165050 DOI: 10.1016/j.drugpo.2020.102710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
302 Mahanama AIK, Samaraweera B, Niroshanie TT, Seethagala SSSAK, Abeynayake JI. Seroprevalence of hepatitis B and C virus infection among clinically suspected patients at state sector hospitals in Sri Lanka; a laboratory-based retrospective study. Infect Dis (Lond) 2019;51:706-9. [PMID: 31298063 DOI: 10.1080/23744235.2019.1640387] [Reference Citation Analysis]
303 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal. 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
304 Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. J Thorac Oncol 2020;15:914-47. [PMID: 32179179 DOI: 10.1016/j.jtho.2020.03.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 24.0] [Reference Citation Analysis]
305 Petruzziello A, Marigliano S, Loquercio G, Coppola N, Piccirillo M, Leongito M, Azzaro R, Izzo F, Botti G. Hepatitis C Virus (HCV) genotypes distribution among hepatocellular carcinoma patients in Southern Italy: a three year retrospective study. Infect Agents Cancer 2017;12. [DOI: 10.1186/s13027-017-0162-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
306 Torres-vázquez B, María de Lucas A, García-crespo C, Antonio García-martín J, Fragoso A, Fernández-algar M, Perales C, Domingo E, Moreno M, Briones C. In vitro selection of high affinity DNA and RNA aptamers that detect hepatitis C virus core protein of genotypes 1 to 4 and inhibit virus production in cell culture. Journal of Molecular Biology 2022. [DOI: 10.1016/j.jmb.2022.167501] [Reference Citation Analysis]
307 Lee MY, Chen WC, Hsu WH, Chen SC, Lee JC. Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism. Int J Mol Sci 2019;20:E4569. [PMID: 31540136 DOI: 10.3390/ijms20184569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
308 Oliveira-Filho AB, Aires DWF, Cavalcante NS, Raiol NC, Lisboa BLA, Frade PCR, da Costa LM, Pinheiro LML, Machado LFA, Martins LC, Silva-Oliveira GC, Pinho JRR, Kupek E, Lemos JAR. Hepatitis C Virus among Female Sex Workers: A Cross-Sectional Study Conducted along Rivers and Highways in the Amazon Region. Pathogens 2019;8:E236. [PMID: 31739623 DOI: 10.3390/pathogens8040236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
309 Chernykh E, Leplina O, Oleynik E, Tikhonova M, Tyrinova T, Starostina N, Ostanin A. Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial). Immunol Res 2018;66:31-43. [PMID: 29164490 DOI: 10.1007/s12026-017-8967-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
310 Gaze R, Vasconcellos LCFD. Exposicao ocupacional à hepatite C: saber operário e rotas inexploradas de propagação do vírus. Rev bras saúde ocup 2020;45:e34. [DOI: 10.1590/2317-6369000015319] [Reference Citation Analysis]
311 Matic S, Popovic S, Baskic D, Todorovic D, Vukovic N, Stankovic M, Djurdjevic P, Zdravkovic N, Mijailovic Z. Methanolic Extract of Teucrium Polium Exerts Immunomodulatory Properties in Human Peripheral Blood Mononuclear Cells. Serbian Journal of Experimental and Clinical Research 2020;0:000010247820200018. [DOI: 10.2478/sjecr-2020-0018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
312 Rostoker G. When should iron supplementation in dialysis patients be avoided, minimized or withdrawn? Semin Dial 2019;32:22-9. [PMID: 29956370 DOI: 10.1111/sdi.12732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
313 Kumata R, Ito J, Takahashi K, Suzuki T, Sato K. A tissue level atlas of the healthy human virome. BMC Biol 2020;18:55. [PMID: 32493363 DOI: 10.1186/s12915-020-00785-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
314 Shimizu Y, Shirasago Y, Kondoh M, Suzuki T, Wakita T, Hanada K, Yagi K, Fukasawa M. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model. J Virol 2018;92:e02258-17. [PMID: 29437969 DOI: 10.1128/JVI.02258-17] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
315 Mundim AEFM, de Castro FOF, Albuquerque MBB, Vilanova-Costa CAST, Pfrimer IAH, Silva AMTC. Major mutations in the NS3 gene region of hepatitis C virus related to the resistance to direct acting antiviral drugs: a systematic review. Virusdisease 2020;31:220-8. [PMID: 32904849 DOI: 10.1007/s13337-020-00616-9] [Reference Citation Analysis]
316 Al-Amad SH. Willingness of dentists in the United Arab Emirates to perform restorative and surgical treatments for patients infected with hepatitis C. Arch Public Health 2021;79:230. [PMID: 34933688 DOI: 10.1186/s13690-021-00756-4] [Reference Citation Analysis]
317 Mousawee SMR, Moossavi M, Bahrami A, Rasekh H, Naghizadeh MS, Abd H, Fereidouni M. The Prevalence of Hepatitis B, Hepatitis C and Human Immunodeficiency Viral Infections Among a Large Population of Afghans. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.101012] [Reference Citation Analysis]
318 Reiser M, Wiebner B, Hirsch J; German Liver Foundation. Neural-network analysis of socio-medical data to identify predictors of undiagnosed hepatitis C virus infections in Germany (DETECT). J Transl Med 2019;17:94. [PMID: 30890175 DOI: 10.1186/s12967-019-1832-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
319 Miri HH, Fazeli P, Ali-Hassanzadeh M, Bemani P, Kabelitz D, Kalantar K. Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: systematic review and meta-analysis. Arch Virol 2021;166:2469-78. [PMID: 34216268 DOI: 10.1007/s00705-021-05141-8] [Reference Citation Analysis]
320 Caroleo B, Colangelo L, Perticone M, De Sarro G, Gallelli L. Efficacy and Safety of Elbasvir-Grazoprevir Fixed Dose in the Management of Polytreated HCV Patients: Evidence From Real-Life Clinical Practice. J Clin Pharmacol 2018;58:1248-53. [PMID: 29746724 DOI: 10.1002/jcph.1135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
321 Prasad M, Saade GR, Sandoval G, Hughes BL, Reddy UM, Mele L, Salazar A, Varner MW, Gyamfi-Bannerman C, Thorp JM Jr, Tita ATN, Swamy GK, Chien EK, Casey BM, Peaceman AM, El-Sayed YY, Iams JD, Gibbs RS, Sibai B, Wiese N, Kamili S, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women: Identifying Seroprevalence and Risk Factors. Obstet Gynecol 2020;135:778-88. [PMID: 32168224 DOI: 10.1097/AOG.0000000000003754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
322 Aboubakar M, Kpossou AR, Glago BRGH, Aguiah AG, Mboreha ZH, Sehonou J. [Prevention and factors associated with anti-HCV carriage in pregnant women living in Cotonou]. Pan Afr Med J 2020;36:182. [PMID: 32952826 DOI: 10.11604/pamj.2020.36.182.23122] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
323 Castro GLC, Amoras EDGS, Araújo MSM, Conde SRSDS, Vallinoto ACR. Hepatitis C virus genotypes and associated risk factors in the state of Pará, Northern Brazil. Braz J Infect Dis 2020;24:304-9. [PMID: 32735876 DOI: 10.1016/j.bjid.2020.06.010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
324 Uribe-Noguez LA, Mata-Marín JA, Ocaña-Mondragón A, Pompa-Mera EN, Ribas-Aparicio RM, Arroyo-Anduiza CI, Gomez-Torres ME, Chaparro-Sánchez A, Gaytán-Martínez J, Mauss S. Comparison of direct sequencing of the NS5B region with the Versant HCV genotype 2.0 assay for genotyping of viral isolates in Mexico. J Infect Chemother 2020;26:205-10. [PMID: 31537472 DOI: 10.1016/j.jiac.2019.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
325 Young KG, Haq K, MacLean S, Dudani R, Elahi SM, Gilbert R, Weeratna RD, Krishnan L. Development of a recombinant murine tumour model using hepatoma cells expressing hepatitis C virus nonstructural antigens. J Viral Hepat 2018;25:649-60. [PMID: 29316037 DOI: 10.1111/jvh.12856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
326 Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One 2019;14:e0217964. [PMID: 31170246 DOI: 10.1371/journal.pone.0217964] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
327 Shoja Z, Chenari M, Jafarpour A, Jalilvand S. Role of iron in cancer development by viruses. Rev Med Virol 2019;29:e2045. [PMID: 30994254 DOI: 10.1002/rmv.2045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
328 da Costa Marques Borges LF, Zalis MG, Santoro-Lopes G, Varella RB. Hepatitis C virus genotypes in hemodialysis patients in Angola. J Med Virol 2019;91:518-21. [PMID: 30381830 DOI: 10.1002/jmv.25354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
329 Palanisamy N, Akaberi D, Lennerstrand J. Protein backbone flexibility pattern is evolutionarily conserved in the Flaviviridae family: A case of NS3 protease in Flavivirus and Hepacivirus. Molecular Phylogenetics and Evolution 2018;118:58-63. [DOI: 10.1016/j.ympev.2017.09.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
330 Reyes-Urueña J, Celly A, Moreno S, Majó X, Colom J, Casabona J. Hepatitis C virus: Testing rate and attrition at linkage to specialized care, Catalonia, Spain 2011-2016. J Viral Hepat 2021;28:288-99. [PMID: 33098176 DOI: 10.1111/jvh.13427] [Reference Citation Analysis]
331 Mota Pereira F, Neves Santos FL, da Conceição Almeida Chagas M, Perez Carreiro R, Kalabric Silva L, Galvão Castro B, Rios Grassi MF. Seroprevalence and Spatial Distribution of Hepatitis C Virus in Bahia, Brazil. Am J Trop Med Hyg 2021:tpmd201615. [PMID: 34424863 DOI: 10.4269/ajtmh.20-1615] [Reference Citation Analysis]
332 Zhang J, Sun W, Lin J, Tian Y, Ma L, Zhang L, Zhu Y, Qiu W. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China. BMC Infect Dis 2019;19:645. [PMID: 31324230 DOI: 10.1186/s12879-019-4217-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
333 Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S. Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review. J Clin Transl Hepatol. 2017;5:343-362. [PMID: 29226101 DOI: 10.14218/jcth.2017.00021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 7.6] [Reference Citation Analysis]
334 Verma D, Ashkar C, Saab S. Cost effectiveness of direct acting antivirals in the treatment of hepatitis C in vulnerable populations. Expert Rev Pharmacoecon Outcomes Res 2021;21:9-12. [PMID: 33073620 DOI: 10.1080/14737167.2021.1838898] [Reference Citation Analysis]
335 Bashir MH, Fazili J, Madhoun MF, Kanagala R, Chen S, Nusrat S. Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis. Eur J Gastroenterol Hepatol 2018;30:296-301. [PMID: 29200006 DOI: 10.1097/MEG.0000000000001032] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
336 Atlaw D, Sahiledengle B, Tariku Z. Hepatitis B and C virus infection among healthcare workers in Africa: a systematic review and meta-analysis. Environ Health Prev Med 2021;26:61. [PMID: 34078258 DOI: 10.1186/s12199-021-00983-9] [Reference Citation Analysis]
337 Sangiorgi D, Perrone V, Buda S, Boglione L, Cariti G, Lefevre C, Nappi C, Degli Esposti L. Epidemiology, patient profile, and health care resource use for hepatitis C in Italy. Clinicoecon Outcomes Res 2017;9:609-16. [PMID: 29066922 DOI: 10.2147/CEOR.S136456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
338 Huang R, Rao H, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun J, Jiang J, Wei L. A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D. Health Qual Life Outcomes. 2018;16:124. [PMID: 29903024 DOI: 10.1186/s12955-018-0941-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
339 Kassem NM, Kassem HA, Ibrahim M, Zawam H, Hamada E. The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients. J Egypt Natl Canc Inst 2020;32:43. [PMID: 33244648 DOI: 10.1186/s43046-020-00054-0] [Reference Citation Analysis]
340 Yechezkel I, Law M, Tzarum N. From Structural Studies to HCV Vaccine Design. Viruses 2021;13:833. [PMID: 34064532 DOI: 10.3390/v13050833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Laugel E, Hartard C, Jeulin H, Berger S, Venard V, Bronowicki JP, Schvoerer E. Full-length genome sequencing of RNA viruses-How the approach can enlighten us on hepatitis C and hepatitis E viruses. Rev Med Virol 2021;31:e2197. [PMID: 34260779 DOI: 10.1002/rmv.2197] [Reference Citation Analysis]
342 Ranjbar Kermani F, Amini-kafiabad S, Mousavi Hosseini K, Maghsudlu M, Sharifi Z, Mansournia MA. Distribution of Hepatitis C Virus Genotypes and Related Risk Factors Among Iranian Blood Donors: A Penalized Logistic Regression. Jundishapur J Microbiol 2018;11. [DOI: 10.5812/jjm.69136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
343 Kpossou AR, Kouwakanou B, Sokpon CNDM, Alassane KS, Bankolé MM, Ahouada C, Vignon RK, Zoundjiekpon V, Sourokou F, Séhonou J, Kodjoh N. [Seroprevalence of hepatitis C virus (HCV) antibodies and associated factors based on voluntary screening data collection in the general population in Benin in 2016]. Pan Afr Med J 2021;40:30. [PMID: 34733398 DOI: 10.11604/pamj.2021.40.30.28775] [Reference Citation Analysis]
344 Iwamoto M, Calzia A, Dublineau A, Rouet F, Nouhin J, Yann S, Pin S, Sun C, Sann K, Dimanche C, Lastrucci C, Coulborn RM, Maman D, Dousset JP, Loarec A. Field evaluation of GeneXpert® (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia. J Viral Hepat 2019;26:38-47. [PMID: 30199587 DOI: 10.1111/jvh.13002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
345 Fadl N, Salem TZ. Hepatitis C genotype 4: A report on resistance-associated substitutions in NS3, NS5A, and NS5B genes. Rev Med Virol 2020;30:e2120. [PMID: 32478480 DOI: 10.1002/rmv.2120] [Reference Citation Analysis]
346 Konstantinides P, Alexopoulou A, Hadziyannis E, Kanellopoulou T, Dourakis SP. Interleukin-17A and B-cell activating factor in chronic hepatitis C patients with or without asymptomatic mixed cryoglobulinemia: effects of antiviral treatment and correlations with vitamin D. Ann Gastroenterol 2018;31:705-11. [PMID: 30386121 DOI: 10.20524/aog.2018.0310] [Reference Citation Analysis]
347 Mui UN, Haley CT, Tyring SK. Viral Oncology: Molecular Biology and Pathogenesis. J Clin Med 2017;6:E111. [PMID: 29186062 DOI: 10.3390/jcm6120111] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 9.6] [Reference Citation Analysis]
348 Soria A, Fava M, Bernasconi DP, Lapadula G, Colella E, Valsecchi MG, Migliorino GM, D'ambrosio R, Landonio S, Schiavini M, Spinetti A, Carriero C, Degasperi E, Cologni G, Gatti F, Viganò P, Hasson H, Uberti‐foppa C, Pasulo L, Baiguera C, Rossotti R, Vinci M, Puoti M, Giorgini A, Menzaghi B, Lombardi A, Pan A, Aghemo A, Grossi PA, Boldizzoni R, Colombo S, Viganò M, Rumi MG, Del Poggio P, Valenti L, Giglio O, De Bona A, d'Arminio Monforte A, Colombo A, Spinelli O, Pigozzi MG, Molteni C, Bonfanti P, Terreni N, Perini P, Capretti A, Bella D, Liani C, Polo S, Aimo G, Pagnucco L, Bhoori S, Centenaro R, Graffeo M, Ciaccio A, Dionigi E, Lazzaroni S, Carderi I, Di Marco M, Rizzardini G, Noventa F, Lampertico P, Fagiuoli S. Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort. Liver Int 2020;40:769-77. [DOI: 10.1111/liv.14386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
349 Zahoor S, Khan A, Asif S, Tabraiz SA, Mustafa H, Ansar S, Hanif S, Raza HA. Past and Future Perspectives for Hepatitis B and C in Pakistan. Cureus 2021;13:e17521. [PMID: 34603891 DOI: 10.7759/cureus.17521] [Reference Citation Analysis]
350 Han Q, Fan X, Wang X, Wang Y, Deng H, Zhang X, Zhang K, Li N, Liu Z. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting. Virol J 2019;16:74. [PMID: 31159813 DOI: 10.1186/s12985-019-1184-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
351 Bettaieb J, Chouikha A, Khedhiri M, Kharroubi G, Badreddine M, Bel Hadj Hmida N, Gharbi A, Hammemi W, Sadraoui A, Ben Yahia A, Meddeb Z, Ben Salah A, Triki H. Hepatitis C virus epidemiology in Central-West Tunisia: a population-based cross-sectional study. Arch Virol 2019;164:2243-53. [PMID: 31179516 DOI: 10.1007/s00705-019-04308-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
352 Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol 2022; 28(1): 96-107 [DOI: 10.3748/wjg.v28.i1.96] [Reference Citation Analysis]
353 Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev Clin Pharmacol 2020;13:1001-46. [PMID: 32838584 DOI: 10.1080/17512433.2020.1814743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
354 Raad II, Chaftari AM, Torres HA, Ayoub EM, Narouz LI, Bartek J, Hachem R. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol 2018; 10(9): 549-557 [PMID: 30310533 DOI: 10.4254/wjh.v10.i9.549] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
355 Husseini AA, Islam Saeed KM, Yurdcu E, Bozdayı AM. Molecular epidemiology of Hepatitis B virus, Hepatitis C virus, and Hepatitis D virus in general population of Afghanistan. Turk J Gastroenterol 2020;31:658-66. [PMID: 33090103 DOI: 10.5152/tjg.2020.19169] [Reference Citation Analysis]
356 Abdel-Tawab MS, Fouad HH, Omran DA, Abdou AE, Zaied SM, Mohamed AA. Evaluation of Serum and Gene Expression of Galectin-4, Interleukin-27, and Complement-7 in Hepatitis C Virus-Infected Egyptian Patients. Biomed Res Int 2020;2020:8879758. [PMID: 33381596 DOI: 10.1155/2020/8879758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
357 Zakareya T, Elhelbawy M, Elzohry H, Eltabbakh M, Deif M, Abbasy M. Long-Term Impact of Hepatitis C Virus Eradication on Liver Stiffness in Egyptian Patients. Can J Gastroenterol Hepatol 2021;2021:4961919. [PMID: 34589447 DOI: 10.1155/2021/4961919] [Reference Citation Analysis]
358 Hussein NR, Sharaf HA, Mahdi S. The Prevalence of Hepatitis C Virus Infection in Pregnant Women in Duhok City, Kurdistan Region of Iraq: A Brief Report. Women Health Bull 2019;In Press. [DOI: 10.5812/whb.91494] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
359 Bardach A, Hernández-Vásquez A, Palacios A, Calderón M, Soto N, Balan D, Augustovski F. Epidemiología, consumo de recursos y costos del manejo médico de la Hepatitis C en Argentina, Colombia, Uruguay y Venezuela. Value Health Reg Issues 2019;20:180-90. [PMID: 31654963 DOI: 10.1016/j.vhri.2019.06.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
360 Ahsan A, Dar S, Hassan F, Ghafoor F, Yousuf MH, Shahzad-Ul-Hussan S. Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus. PLoS One 2021;16:e0256816. [PMID: 34449828 DOI: 10.1371/journal.pone.0256816] [Reference Citation Analysis]
361 Aydin Y, Chedid M, Chava S, Danielle Williams D, Liu S, Hagedorn CH, Sumitran-Holgersson S, Reiss K, Moroz K, Lu H, Balart LA, Dash S. Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture. Sci Rep 2017;7:9223. [PMID: 28835697 DOI: 10.1038/s41598-017-10087-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
362 Lee CY, Wu PH, Lu MW, Chen TC, Lu PL. High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan. PLoS One 2021;16:e0251158. [PMID: 33956867 DOI: 10.1371/journal.pone.0251158] [Reference Citation Analysis]
363 Xia Q, Shu Z, Ye T, Zhang M. Identification and Analysis of the Blood lncRNA Signature for Liver Cirrhosis and Hepatocellular Carcinoma. Front Genet 2020;11:595699. [PMID: 33365048 DOI: 10.3389/fgene.2020.595699] [Reference Citation Analysis]
364 Talal AH, Andrews P, Mcleod A, Chen Y, Sylvester C, Markatou M, Brown LS. Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone. Clin Infect Dis. 2019;69:323-331. [PMID: 30329042 DOI: 10.1093/cid/ciy899] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
365 Marín MQ, Pérez P, Ljungberg K, Sorzano CÓS, Gómez CE, Liljeström P, Esteban M, García-Arriaza J. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV. J Virol 2019;93:e00055-19. [PMID: 30674625 DOI: 10.1128/JVI.00055-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
366 Li J, Gordon SC, Rupp LB, Zhang T, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Lu M;  CHeCS Investigators. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Aliment Pharmacol Ther. 2019;49:599-608. [PMID: 30650468 DOI: 10.1111/apt.15102] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
367 Picarazzi F, Vicenti I, Saladini F, Zazzi M, Mori M. Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. Molecules 2020;25:E5695. [PMID: 33287144 DOI: 10.3390/molecules25235695] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
368 Boraie MB, Elnaggar YA, Ahmed MO, Mahmoud AM. Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study). Diabetes Metab Syndr 2019;13:2641-6. [PMID: 31405688 DOI: 10.1016/j.dsx.2019.07.032] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
369 Hussain Y, Shahzad A, Azam S, Munawar N. Hepatitis-C and it's seroconversion in end stage kidney disease patients on maintenance hemodialysis and factors affecting it. Pak J Med Sci 2019;35:66-70. [PMID: 30881398 DOI: 10.12669/pjms.35.1.366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
370 Yen H, Chen Y, Lai J, Chen H, Yao C, Huang S, Liu I, Zeng Y, Yang F, Siao F, Chen M, Su P. Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis. JCM 2022;11:1853. [DOI: 10.3390/jcm11071853] [Reference Citation Analysis]
371 Smibert OC, Paraskeva MA, Westall G, Snell G. An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients. Paediatr Drugs 2018;20:539-53. [PMID: 30187362 DOI: 10.1007/s40272-018-0313-1] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
372 Jia B, Yu D, Yu G, Cheng Y, Wang Y, Yi X, Li X, Wang Y. Naringenin improve hepatitis C virus infection induced insulin resistance by increase PTEN expression via p53-dependent manner. Biomed Pharmacother 2018;103:746-54. [PMID: 29684853 DOI: 10.1016/j.biopha.2018.04.110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
373 Mattingly TJ 2nd, Love BL, Khokhar B. Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review. Pharmacoeconomics 2020;38:927-39. [PMID: 32533524 DOI: 10.1007/s40273-020-00933-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
374 Wu Q, Li Z, Liu Q. An important role of SREBP-1 in HBV and HCV co-replication inhibition by PTEN. Virology 2018;520:94-102. [PMID: 29803738 DOI: 10.1016/j.virol.2018.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
375 El-Ghitany EM, Alkassabany YM, Farghaly AG. Performance and modification of EGCRISC among hepatitis C virus high-risk groups. Epidemiol Infect 2020;148:e28. [PMID: 32054561 DOI: 10.1017/S0950268820000175] [Reference Citation Analysis]
376 Okui T. An age-period-cohort analysis of mortality rates for stomach, colorectal, liver, and lung cancer among prefectures in Japan, 1999-2018. Environ Health Prev Med 2020;25:80. [PMID: 33278883 DOI: 10.1186/s12199-020-00922-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
377 Muhamad NA, Ab Ghani RM, Abdul Mutalip MH, Muhammad EN, Mohamad Haris H, Mohd Zain R, Abdullah N, Muhammad Azami NA, Abd Jalal N, Ismail N, Mhd Yusuf NA, Othman R, Kamalul Arifin AS, Abdullah MS, Kamaruddin MA, Abu Hassan MR, Aris T, Jamal R. Seroprevalence of hepatitis B virus and hepatitis C virus infection among Malaysian population. Sci Rep 2020;10:21009. [PMID: 33273475 DOI: 10.1038/s41598-020-77813-5] [Reference Citation Analysis]
378 Wu CM, Su FH, Muo CH, Huang JC, Wu MM, Yeh CC. Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin. Viruses 2021;13:475. [PMID: 33799370 DOI: 10.3390/v13030475] [Reference Citation Analysis]
379 Marín MQ, Sliepen K, García-Arriaza J, Koekkoek SM, Pérez P, Sorzano CÓS, Gómez CE, Sanders RW, Esteban M. Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. Vaccines (Basel) 2020;8:E440. [PMID: 32764419 DOI: 10.3390/vaccines8030440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
380 Clifford GM, Waterboer T, Dondog B, Qiao YL, Kordzaia D, Hammouda D, Keita N, Khodakarami N, Raza SA, Sherpa AT, Zatonski W, Pawlita M, Plummer M, Franceschi S. Hepatitis C virus seroprevalence in the general female population of 9 countries in Europe, Asia and Africa. Infect Agent Cancer 2017;12:9. [PMID: 28168002 DOI: 10.1186/s13027-017-0121-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
381 Ul Abideen Z, Siddique S, Nasrullah I, Khan JS, Rehman S, Tong Y, Qamar R, Butt AM. A 2-year retrospective study of viral and host-associated risk factors in Pakistani hepatocellular carcinoma patients. Eur J Gastroenterol Hepatol 2019;31:1103-9. [PMID: 30829691 DOI: 10.1097/MEG.0000000000001384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Chen R, Li D, Zhang M, Yuan X. Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors. Ann Transplant 2021;26:e933313. [PMID: 34489392 DOI: 10.12659/AOT.933313] [Reference Citation Analysis]
383 Zhang J, Gao X, Yuan Y, Sun C, Zhao Y, Xiao L, Yang Y, Gu Y, Yang R, Hu P, Zhang L, Wang C, Ye J. Perilipin 5 alleviates HCV NS5A-induced lipotoxic injuries in liver. Lipids Health Dis 2019;18:87. [PMID: 30954078 DOI: 10.1186/s12944-019-1022-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
384 Ahmed R, Kareem R, Venkatesan N, Botleroo RA, Ogeyingbo OD, Bhandari R, Gyawali M, Elshaikh AO. Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection. Cureus 2021;13:e17237. [PMID: 34540464 DOI: 10.7759/cureus.17237] [Reference Citation Analysis]
385 Nasimzadeh S, Azaran A, Jalilian S, Makvandi M, Seyedian SS, Keikhaei B, Mehr FJ. Prevalence of occult hepatitis C virus infection in beta-thalassemia major patients in Ahvaz, Iran. Arch Virol 2021;166:2703-10. [PMID: 34275067 DOI: 10.1007/s00705-021-05126-7] [Reference Citation Analysis]
386 Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 [PMID: 31802834 DOI: 10.3748/wjg.v25.i44.6551] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
387 Ashraf MU, Iman K, Khalid MF, Salman HM, Shafi T, Rafi M, Javaid N, Hussain R, Ahmad F, Shahzad-Ul-Hussan S, Mirza S, Shafiq M, Afzal S, Hamera S, Anwar S, Qazi R, Idrees M, Qureshi SA, Chaudhary SU. Evolution of efficacious pangenotypic hepatitis C virus therapies. Med Res Rev 2019;39:1091-136. [PMID: 30506705 DOI: 10.1002/med.21554] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
388 Qian H, Chao X, Williams J, Fulte S, Li T, Yang L, Ding WX. Autophagy in liver diseases: A review. Mol Aspects Med 2021;:100973. [PMID: 34120768 DOI: 10.1016/j.mam.2021.100973] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
389 Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res 2021;149:1-61. [PMID: 33579421 DOI: 10.1016/bs.acr.2020.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
390 Yabaji PM, Shankarkumar A, Shukla A, Bhatia S. Hepatitis C virus infection in a tertiary care hospital in Mumbai, India: Identification of a mixed and novel genotype. Indian J Med Microbiol 2018;36:352-6. [PMID: 30429386 DOI: 10.4103/ijmm.IJMM_18_221] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
391 Ye D, Tang Y, Gu Y, Haleem H, Zhang L, Zhang Y, Xu C, Zhao J. Evaluation of the effectiveness of a pilot study of hospital-based hepatitis C epidemic surveillance. Medicine (Baltimore) 2019;98:e18334. [PMID: 31860986 DOI: 10.1097/MD.0000000000018334] [Reference Citation Analysis]
392 Homolak J, Tomljanović D, Milošević M, Vražić D, Živković M, Budimir I, Pezo Nikolić B, Muslim A, Ljubičić N, Nikolić M. A CROSS-SECTIONAL STUDY OF HEPATITIS B AND HEPATITIS C KNOWLEDGE AMONG DENTAL MEDICINE STUDENTS AT THE UNIVERSITY OF ZAGREB. Acta Clin Croat 2021;60:216-30. [PMID: 34744271 DOI: 10.20471/acc.2021.60.02.07] [Reference Citation Analysis]
393 Xiang Y, Lai XF, Chen P, Yang Y. The correlation of HCV RNA and HCV core antigen in different genotypes of HCV. J Clin Lab Anal 2019;33:e22632. [PMID: 30069909 DOI: 10.1002/jcla.22632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
394 Simicic P, Grgic I, Santak M, Vince A, Lepej SZ. Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia. Microb Pathog 2019;136:103694. [PMID: 31446041 DOI: 10.1016/j.micpath.2019.103694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
395 Namayandeh M, Jamalidoust M, Heydari Marandi N, Aliabadi N, Ziyaeyan A, Pouladfar G, Ziyaeyan M. Hepatitis C virus genotypes in patients with chronic hepatitis C infection in southern Iran from 2016 to 2019. Microbiol Immunol 2020;64:762-7. [PMID: 32902892 DOI: 10.1111/1348-0421.12845] [Reference Citation Analysis]
396 Shayan SJ, Nazari R, Kiwanuka F. Prevalence of HIV and HCV among injecting drug users in three selected WHO-EMRO countries: a meta-analysis. Harm Reduct J 2021;18:59. [PMID: 34044849 DOI: 10.1186/s12954-021-00505-4] [Reference Citation Analysis]